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1 General Introduction 
1.1 Introduction 
Paragangliomas (PGLs) are highly vascular, neuroendocrine tumors of paraganglia, cell 
clusters originating from the neural crest, that have co migrated with the autonomic nervous 
system (1).In general, paragangliomas in the head and neck region (HNPGL; also called 
glomus tumors) are associated with the parasympathic system, whereas adrenal and extra-
adrenal non-HNPGLs are associated with the sympathetic nervous system. Adrenal 
paragangliomas are also refered to as pheochromocytomas. In the medulla of the adrenal 
glands neural crest cells ultimately result in formation of chromaffin cells that are able to 
produce and secrete catecholamines. In addition, most extra-adrenal non-HNPGLs produce 
catecholamines as well.  Although HNPGL have the potential to produce and secrete 
catecholamines, only a minority of these patients actually have biochemical evidence of 
catecholamine excess (2). PGL can occur either sporadically or hereditary, as part of a 
familial syndrome (MEN-2, NF1, VHL or familial PGL, due to mutations in cRET, NF1, 
VHL and SDH respectively) (3-9). 
Figure 1: Distribution of the paraganglion system  
   
Adapted from: J.C. Jansen, P.B. Douwes Dekker. Coutesy of AFIP, tumors of the extra-adrenal paraganglion 







Paragangliomas and pheochromocytomas can occur as a consequence of a mutation in the 
succinate dehydrogenase (SDH) gene. The SDH gene family (SDHA, SDHB, SDHC and 
SDHD) encodes the four subunits of complex II of the mitochondrial electron transport 
chain. The nature of the germline mutations in complex II subunits predicts loss of function 
of the mutant variants (10). The subsequent somatic loss of the non mutant alleles in these 
tumors suggest that these genes function as tumor suppressor genes in the paraganglionic 
system (11). Although the molecular steps linking loss of complex II subunits to cellular 
proliferation are unknown (11), two plausible hypotheses have been proposed to explain the 
linkage between disruption of electron flow through mitochondrial complex II and 
tumorigenesis in neuro-endocrine cells. SDH contributes to the energy metabolism as a 
component of the tricarboxylic acid cycle, converting succinate to fumarate, and by serving 
as a source of electrons for mitochondrial respiration, as complex II of the electron 
transport chain. In the succinate accumulation hypothesis increased succinate resulting from 
loss of SDH function can inhibit the activity of prolyl hydroxylases (PHDs). PHDs are 
enzymes that are required for the degradation of HIF (hypoxia induced factor). Thus HIF 
becomes activated as a result of SDH loss of function (12;13). Hypoxia induced factors are 
transcription factors that respond to changes in available oxygen in the cellular 
environment, specifically hypoxia. Physiological processes regulated by HIF-1 target genes 
are erythropoiesis, angiogenesis and glycolysis (14). Many types of cancer have been 
associated with elevated levels of hypoxia-induced factor. The second hypothesis is based 
on the data of Lee et al. (Lee et al, Cancer cell 2008:155-167), who reported escape from 
apoptosis of sympathoadrenal progenitor cells at the end of the embryonic period. 
Normally, in the beginning of the embryonic period, there is a lot of nerve growth factor 
which inhibits apoptosis in order for the nervous system to develop. At the end of the 
embryonic period, nerve growth factor decreases considerably, resulting in apoptosis of a 
large proportion of neuronal progenitor cells. In case of mutations in the paparaganglioma 
genes cRET, NF1, VHL and SDH, apoptosis is inhibited, thereby resulting in formation of 
paragangliomas. There is an autosomal-dominant role of transmission for all PGLs with a 
parent of origin dependent inheritance in SDHD mutation carriers. The disease phenotype is 
transmitted only through the fathers, whereas mothers do not transmit the disease (15-17). 
This observation strongly suggests that SDHD is subject to genetic imprinting, although the 
exact molecular mechanism remains unknown. There is no evidence of a parent specific 
disease transmission in families with SDHB or SDHC mutations (3;5;11;18).  
1.3 Pathology 
Paragangliomas are usually well demarcated and often encapsulated. Paragangliomas are 
characterized by its architecture, the tumor cells are arranged in distinctive cell balls, or 
“Zellballen”. These cell balls are separated from one another by a fibrovascular stroma. The 
“Zellballen” are composed of clusters of chief cells that are surrounded by supportive 
sustentacular cells at the periphery. The chief cells have an epitheloid appearance and vary 
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from ovoid to polyhydral (19;20). These chief cells, which are neuro-endocrine cells, 
express neuron specific enolase, serotonin, and chromogranin, and the sustentacular cells 
express S-100 protein (20). Membrane-bound electron-dense neurosecretory granules may 
be seen on electron microscopy (21;22). These neurosecretory granules vary in size, 
configuration and electron density of their cores (22). The sustentacular cells are spindled 
and are devoid of granules. Approximately 10% of HNPGLs are malignant. The histologic 
features of malignant paragangliomas are basically identical to those of benign tumors, but 
may exhibit the following features: central necrosis of Zellballen, vascular and lymphatic 
invasion, and the presence of mitotic spindles (23).  Because there are no accepted 
pathological or immunohistochemical markers that distuingish malignant from benign 
tumors (24), malignancy is only diagnosed when metastasis to non-neuroendocrine tissue is 
demonstrated.  
1.4 Catecholamine biosynthesis 
Catecholamines are molecules that have a catechol nucleus consisting of benzene with two 
hydroxyl side groups plus a side-chain amine. Catecholamines include dopamine, 
norepinephrine and epinephrine. The L-stereoisomer of amino acid tyrosine from a dietary 
source or following hydroxylation of phenylalanine in the liver serves as a substrate for the 
initiation of catecholamine synthesis. It is converted to dihydroxyphenylalanine (dopa) by 
tyrosine hydroxylase (TH) and represents the rate limiting step in catecholamine 
biosynthesis. Tissue expression of this enzyme is largely confined to dopaminergic and 
noradrenergic neurons of the central nervous system, sympathetic nerves of the peripheral 
nervous system, chromaffin cells of the adrenal medulla and extramedullary paraganglia. 
The following step represents the production of dopamine by decarboxylation of dopa 
aromatic L-amino acid decarboxylase. Dopamine formed in neurons and chromaffin cells is 
translocated from the cytoplasm into vesicular storage granules. Large amounts of 
dopamine are also produced as an end product of catecholamine synthesis in peripheral 
non-neuronal cells of the gastrointestinal tract and kidneys. The dopamine formed in 
noradrenergic neurons and chromaffin cells is converted to norepinephrine by dopamine β-
hydroxylase (DBH), an enzyme that is found only in the vesicles of cells that synthesize 
norepinephrine and epinephrine. In adrenal medullary chromaffin cells, norepinephrine is 
metabolized by the cytosolic enzyme phenylethanolamine (PNMT) to form epinephrine.  
Epinehrine is then translocated into chromaffin granules, where the amine is stored 
awaiting release. Expression of PNMT in extra-adrenal paragangliomas is negligent, which 
explains the preferential production of norepinephrine by these tumors, compared to the 
production of both norepinephrine and epinephrine by adrenal pheochromocytomas (25). 
Translocation of catecholamines into vesicular granules for storage is facilitated by two 
vesicular monoamine transporters: VMAT1 and VMAT2 (26). Storage vesicles represent a 
complex functional unit that continuously maintains a highly dynamic equilibrium between 
passive outward leakage of catecholamines into the cytoplasm counterbalanced by 




Figure 2: Pathways of catecholamine synthesis and O-methylation  
 
Courtesy of: Dr. G. Eisenhofer. TH, tyrosine hydroxylase; AADC, aromatic amino acid decarboxylase; DBH, 
dopamine β-hydroxylase; PNMT, phenylethanolamine-N-methyltransferase; COMT, catechol-O- 
methyltransferase. 
Catecholamines share the acid environment of the storage granule matrix with adenosine 
triphosphate (ATP), peptides and proteins, of which the most well known are the 
chromogranins. The chromogranins are ubiquitous components of secretory vesicles, and 
their widespread presence among endocrine tissues has led to their measurement in plasma 
as sensitive, albeit relatively non-specific markers of neuro-endocrine tumors, including 
pheochromocytomas and paragangliomas (27;28). All the free main catecholamines 
(dopamine, norepinephrine and epinephrine) have tightly regulated metabolism and organ-
specific secretion. While dopamine is a major central neurotransmitter, its peripheral levels 
can be elevated in rare dopamine-secreting pheochromocytomas (29;30). The adrenal gland 
can secrete both epinephrine and norepinephrine direct in the circulation, of which about 
90% is rapidly removed by the extra-neuronal hepatic monoamine transport system. 
Paraganglia exclusively secrete norepinephrine, which is a major neurotransmitter within 
the sympathetic nervous system (2). For norepinephrine released by sympathetic nerves ~ 
90% is removed by neuronal reuptake, 5% is removed by extraneuronal uptake and 5% 
escapes these processes to enter the bloodstream. Catechol-O-methyltransferase (COMT) is 
responsible for a major pathway of catecholamine metabolism, catalyzing O-methylation of 
dopamine to methoxytyramine, norepinephrine to normetanephrine and epinephrine to 
normetanephrine. Normetanephrine and metanephrine are produced in small amounts and 
only at extra-neuronal locations, with the single largest source representing adrenal 
chromaffin cells, which account for over 90% of circulating metanephrine and 24-40% of 
circulating normetanephrine. Approximately 90% of the vesicular monoamine (VMA) 
formed in the body is produced in the liver, mainly from hepatic uptake and metabolism of 
circulating DHPG and MHPG. In humans, VMA and the sulphate and glucoronide 
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conjugates of MHPG represent the main end products of norepinephrine and epinephrine 
metabolism and are eliminated mainly by urinary excretion (25). 




Courtesy of: Dr. W.H.A. de Jong. Dopmanine, norepinephrine, and epinephrine are metabolized to free 3-MT, 
NMN, and MN, respectively, by the enzyme catechol-O-methyltransferase (COMT). The free MNs may than be 
conjugated with a sulfate group by the sulfotransferase isoenzyme 1A3 (SULT1A3).  
1.5 Clinical presentation 
1.5.1 Head and neck paragangliomas 
Head and neck paragangliomas usually grow slowly. Only a minority has a growth rate of 
more than 20% (31). Because of this slow grow rate, HNPGL remain clinically silent for 
years. The clinical presentation of head and neck paragangliomas is dominated by local 
mass effects symptoms (2). Carotid body paragangliomas (CBTs) are the most common 
HNPGL. The most common presenting sign is a painless cervical mass (32). When a bruit 
over the mass is present, significant compression of the artery is present (33). Large 
compressive CBTs may result in cranial nerve paralysis, including vagal and hypoglossal 
paralysis. Symptom duration may range from 1 to 5 years prior to the diagnosis.  
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Vagal body paragangliomas present as painless neck masses, located behind the angle of 
the mandible, occasionally accompanied by dysphagia and hoarseness (34). Diagnosis and 
treatment of these tumors is particularly challenging because of the variable clinical 
behavior of these tumors. They generally grow slowly, but have the potential to surround 
and invade neurovascular structures, invade the skull base, and extent intracranially. 
Surgical excision may be associated with considerable morbidity, because of the origin of 
the tumor from the vagus nerve, and the surrounding cranial nerves (34). Paragangliomas of 
the mesotympanicum (glomus tympanicum) and jugular foramen (glomus jugulare) most 
commonly present as a vascular middle ear mass. These tumors often present with pulsatile 
tinnutis and hearing loss (35). Difficulties in speech, swallowing and airway function may 
be the result of dysfunction of cranial nerves traversing the jugular foramen (36). Other 
sites within the head and neck may represent rare locations for paragangliomas. Laryngeal 
paragangliomas may present with hoarseness and dysphagia secondary to mass effect rather 
than neurologic dysfunction (37). Other rare sites for paraganglioma include the sinonasal 
chambers, orbit, thyroid gland and thoracic inlet (19;38-40).  
1.5.2 (Extra-)adrenal paragangliomas 
Germline mutations in the SDHx genes are associated with the development of 
paragangliomas in diverse anatomical locations, including pheochromocytomas. Extra-
adrenal paraganglionic clusters and organs include the organ of Zuckerkandl, prevertebral 
and paravertebral thoraco-abdominal and pelvic paraganglia, and other paraganglia in 
ovary, testis, vagina, urethra, prostate, bladder and liver (1). Whether anatomical locations 
of paragangliomas are influenced by a specific complex II mutation remains to be 
established (11). The clinical presentation of pheochromocyomas and extra-adrenal PGLs is 
highly variable and the clinical profile varies according to the type of catecholamine 
secreted. Most symptoms are due to elevated levels of catecholamines. Sustained 
hypertension is found in more than 50% of adult cases. Palpitations, headache, excess 
sweatiness and pallor are well-known effects of continous or paroxysmal catecholamine 
excess. Other complaints are anxiety, nausea, vomiting, weight loss, dyspnea, weight loss 
or weight gain, and generalized weakness (41;42). Direct stimulation of the tumor, physical 
activity, diagnostic procedures, certain drugs or food may trigger catecholamine release 
(43). Metabolic actions of catecholamines may lead to hyperglycemia and electrolyte 
disturbances as presenting symptoms, which could lead to delayed diagnosis or near-fatal 
complications (44).  
1.5.3 Hereditary versus sporadic tumors 
The major features related to predisposition for inherited disease are: familial antecedents 
of the disease, bilateral tumors affecting paired organs, multiple primary tumors in the same 
individual, tumor type and early age of onset (4;45;46). SDHD gene mutations are more 
prevalent in patients with HNPGL compared to SDHB or –C mutations, although this might 
be regionally different (4;47). Carotid and vagal PGL are more common in patients with a 
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familial form of the disease compared to jugular or tympanic tumors (48). Hereditary 
paragangliomas present earlier than sporadic cases (49). Approximately 10% of patients 
with HNPGL present with multiple tumors (50). In sporadic cases the incidence of multiple 
tumors probably represents unrecognized familial cases, because the chance of developing 
multiple tumors without precipitating factors is small (51). Some studies report a difference 
in female to male ratio between heriditary and sporadic cases. While there are more males 
than females with inherited HNPGL, females in the general population are more likely than 
males to develop sporadic tumors (4;15;52;53). SDHB mutation carriers are more likely to 
present with extra-adrenal non-HNPGLs and pheochromocytomas, solitary tumors, non-
familial presentation, and malignant paragangliomas (49;54-58).  Ninety percent of SDHB 
related pheochromocytomas secrete norepinephrine or dopamine (56). SDHD mutation 
carriers are more likely to present with HNPGLs, multiple tumors and benign 
paragangliomas (49;54;59). At least a third of extra-adrenal PGLs are caused by SDHD or 
SDHB mutations, and at least 28% of malignant pheochromocytomas are caused by SDHB 
germ line mutations (55;57;60). SDHC germ line mutations are characterized mainly by 
solitary HNPGLs and incomplete penetrance (61).  
1.6 Biochemical evaluation 
1.6.1 Head and neck paragangliomas 
Head and neck paragangliomas have the ability to produce and secrete catecholamines (1), 
but only a minority (~5%) of these patients has a biochemical active tumor (2). It is unclear 
which test has the highest sensitivity in discovering a biochemical active head and neck 
paraganglioma.  
1.6.2 (Extra)-adrenal paragangliomas  
The biochemical detection of (extra)-adrenal PGLs depends on the demonstration of 
excessive amounts of catecholamines (62). Because of the episodic secretion pattern of 
catecholamines, false-negative test results may occur. Metanephrines on the other hand, are 
produced continuously within tumor cells and therefore the measurement of these 
metabolites is a very sensitive test for the diagnosis of pheochromocytoma (63). The 
recommendations of the International Symposium on Pheochromocytoma for initial 
diagnosis of pheochromocytoma include measurements of fractionated metanephrines in 
urine or plasma (or both) as available. Both tests offer high diagnostic sensitivity. However, 
taking test specificity in consideration, the measurement of plasma free metanephrines is 
preferred. None of the tests is absolutely sensitive and specific for the diagnosis of 
pheochromocytoma. Dietary constituents or medications can either cause direct analytical 
interference in measurements of catecholamines and metabolite levels or may influence the 
physiological processes that determine these levels (43;64). Therefore, urine and plasma 
samples should be collected under strict dietary regulations and after withdrawal of 
medication for several weeks or after changing antihypertensive medication to doxazosine. 
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The measurement of plasma 3-methoxytyramine has been shown to provide diagnostic 
value in dopamine-secreting pheochromocytoma (64).  
The clonidine suppression test is intended to distinguish between pheochromocytoma and 
false-positive increases in plasma catecholamines and metanephrines. Clonidine acts 
centrally as an alpha 2-adrenergic receptor agonist that normally suppresses the release of 
catecholamines from neurons that does not affect the catecholamine secretion from a 
pheochromocytoma. Clonidine is admitted orally, and plasma catecholamines or 
metanephrines are measured before and after three hours after the dose. Normal plasma 
norepinephrine or normetanephrine levels, or their respective decrease by 50 or 40%, 
exclude pheochromocytoma. Because of the risk of a marked reduction in blood pressure, 
clonidine suppression test should not be performed in hypovolemic patients (65).  
Chromogranin A (CgA) is secreted from neurosecretory vesicles, along with 
catecholamines (66). Plasma CgA levels are elevated in the great majority of patients with 
pheochromocytoma. The levels correlate with tumor mass, making CgA a useful tumor 
marker (28;67). Plasma CgA levels are particularly elevated in patients with malignant 
pheochromocytoma (68). Plasma CgA levels can also be elevated in patients with 
biochemically silent tumors. 
1.7 Radiographical evaluation 
1.7.1 Head and neck paragangliomas 
The diagnostic evaluation of head and neck paragangliomas establishes the type and extent 
of disease, associated lesions, and assesses collateral circulation in the head and neck (69).  
Magnetic resonance imaging (MRI) represents the most important imaging technique for 
evaluation and characterization of head and neck paragangliomas. The IV administration of 
MR contrast media has been recommended to improve tumor detectability. MR imaging 
provides more diagnostic information than does CT scanning, because of the better soft 
tissue contrasts as compared to CT (70). CT scanning is the most useful modality for 
imaging of paragangliomas of the temporal bone. MRI enables multiplanar imaging of 
tumor extension and vessel encasement. The recommended MR pulse sequences should at 
least include a T1 weighted spine echo and a T2 weighted turbo spin echo sequence. T2 
weight fat suppressed and contrast enhanced fat-suppressed T1 weighed sequences can 
offer additional diagnostic information for improved depiction of paragangliomas in the 
skull base region, but have not proven to be as effective as pre- and post-contrast enhanced 
3D Time of Flight (TOF) MR angiography sequence (71). The MR appearance is that of a 
lesion exhibiting low signal intensity T1 and proton density weighted images and a high 
signal intensity on T2 weighted images. Paragangliomas of the head and neck are 
hypervascular. MRI arteriography/ venography characterize arterial and venous structures 
in a non-invasive fashion. MRI arteriography provides illustrations of the pertinent arterial 
anatomy with attendant displacement of vessels and characterization of dominant vascular 
supply, which may be important if surgery is being considered (72). Venography with MRI 
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allows for illustration of any abnormalities of the jugular bulb, internal jugular vein and 
pertinent dural sinuses including compression and/or thrombosis (73). In addition, 
paragangliomas express somatostatin receptor type 2 on their cell surface. Octreotide is a 
somatostatin analogue that, when coupled to a radioisotope, produces a scintigraphic image 
of neuroendocrine tumors expressing somatostatin type 2 receptors (SSR2) (74;75). 
Octreotide scintigraphy has a sensitivity of 97% and a specificity of 83% in the detection of 
HNPGL (76). Octreotide scintigraphy also appears to be useful in the detection of 
synchronous tumors and metastases in the screening of patients with hereditary PGL (76-
78). Somatostatin receptor scintigraphy has also been recommended in the detection of 
local recurrence or residual tumor after surgery (79). 
123
-metaiodobenzylguanidine is a 
radiolabeld compound that can be used to detect paragangliomas. 
123
-
metaiodobenzylguanidine provides important information if patients with unresectable 
tumors are suitable for treatment with 
123
-metaiodobenzylguanidine. Ultrasound has a 
limited role in the evaluation of HNPGL. It may be usefull in the evaluation and follow-up 
of carotid body paraganglioams. Carotid body paragangliomas can be visualized as 
hypoechoic heterogeneous masses, which can splay the internal and external carotid arteries 
(80). 
1.7.2 (Extra)-adrenal paragangliomas 
SDH-related tumour localization studies should be carried out after biochemical diagnosis 
suggested existing disease in agreement with diagnostic approach to other PGLs. SDHB 
mutation carriers can develop biochemically silent malignant PGLs. Therefore, screening 
for these tumors should not be limited to biochemical tests (81). Both CT- and MRI 
scanning are sensitive anatomical imaging modalities, but lack specificity (82;83;83). 
Functional imaging techniques are able to show functional tissue. MIBG scanning is the 
most widely used tracer in the first line functional imaging of PGL. The sensitivity is high 
for primary tumors and relatively poor for metastasis (84;85). F-DOPA-PET has been 
confirmed to be usefull in the evaluation of sympathetic and parasympathetic PGL (86;87). 
18
F-FDG PET/CT is the preferred technique for the localization of the primary PGL and to 
rule out metastases. Alternatives are 
18
F-DOPA PET and 
123
I-MIBG scintigraphy. For 
patients with known metastatic PGL, 
18










F-FDA PET in non-SDHB patients (88). 
1.8 Treatment 
1.8.1 Head and neck paragangliomas 
Treatment of head and neck paragangliomas must be considered in relation to the tumor 
growth velocity, biological activity of the tumor, patient age and medical condition, tumor 
size and site, and potential for treatment related morbidity (89). Because most tumors grow 
slow, a wait-and-scan policy is often advised (31). The main treatment modalities for 
HNPGL are mainly surgery. Surgical success is measured by total tumor resection without 
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recurrence. Treatment options and recommendations vary across the spectrum of 
paragangliomas. A team approach is recommended for the treatment of most 
paragangliomas except for the very small tumors. Familial paragangliomas can be detected 
earlier due to screening. This allows for removal while still small. A functional HNPGL 
should be recognized preoperatively to allow pharmacological preparation to prevent or 
block the effects of acute release of catecholamines during anesthesia induction and surgery 
that may potentially produce lethal complications (90). α-Adrenergic blockage is the anti-
hypertensive treatment of choice to prevent intraoperative hypertensive crisis. Clinically 
and biochemically silent paragangliomas may cause hemodynamic instability when they are 
manipulated during surgery (2). Surgical resection has been the mainstay of treatment of 
CBTs (91). Surgical morbidity has been reduced as a consequence of improvement in 
anesthesia and vascular surgical technique (92). The risk of arterial injury during surgery 
increases with increasing tumor size (92;93). Surgical resection of bilateral CBTs 
represents a potential problem with complete loss of the carotid chemo- and baroreceptor 
function (93-96). Surgical morbidity related to cranial nerve dysfunction is more common 
in vagal body surgery compared to carotid body resection. Nevertheless, surgical resection 
has traditionally been advocated. During the process of decision taking the following points 
should be taken into consideration: tumor size; age of the patient; monofocal or plurifocal 
nature of the tumor; growth rate of the tumor and 10
th
 cranial nerve loss (97;98). Excision 
of vagal paraganglioma almost always requires sacrifice of the vagus nerve (99). Resection 
of these tumors may also be associated with significant vascular injury, especially for larger 
tumors at the skull base (100). Given the potential for significant morbidity as a result of 
cranial nerve sacrifice or vascular injury, patient selection should be carefully considered 
prior to recommending surgery for vagal paraganglioma. A wait and scan policy is 
preferable to aggressive surgery for patients at risk for disabling surgical morbidity (50). 
Glomus jugulare tumors originate in the jugular bulb region. Symptamotology is 
determined by its variable growth pattern. Management of glomus jugulare tumors remains 
controversial. The surgical approach must be individualized to accommodate the route of 
tumor extension. Surgical control of the tumor can be expected in 85% of cases, tumor 
recurrence is seen in approximately 4.9% and subtotal resection approximates 10%. The 
subject of pre-embolization in managing head and neck paragangliomas remains a subject 
of controversy. The primary aim of pre-operative embolization is to reduce tumor 
vascularity which can lead to a decreased intra-operative blood loss (101). This leads to a 
better operative field for the surgeon, reducing the possibility of nerve or vessel damage. 
There is no evidence that pre-operative embolization reduces tumor dimension. To obtain 
the best result after selective embolization, it is recommended to perform surgery within the 
first 48h to minimize revascularization edema and local inflammatory response (102). An 
experienced vascular radiology team has to be familiar with the complexity and possible 
variations in head and neck vascular anatomy. The goal of surgical resection is complete 
tumor removal. Cervical paragangliomas are usually resected via a transcervical approach. 
The approach choosen for resection of a temporal paraganglioma depends on the location 
and extend of the tumor. Surgical resection carries a mortality rate of 3 to 15% (103).  The 
rate of complications rises with the size of the tumor (89). The most common complication 
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is cranial nerve damage, observed in 18 to 50% of patients (104). Vascular complications 
account for a total of 9-28% with an estimated risk for stroke up to 11% (105). The role of 
tumor irradiation in the management of paragangliomas remains controversial. External 
tumor irradiation may reduce tumor growth and may provide symptomatic relieve in a 
selected subpopulation of patients. The indications for tumor irradiation may be large 
tumors, in which resection may result in considerable morbidity, poor health of the patient, 
after incomplete resection of the tumor with intracranial or skull base invasion (101) or in 
the setting of multiple HNPGLs (106). Radiotherapy judges treatment efficiency by the 
absence of tumor growth assessed radiographically.  
1.8.2(Extra)-adrenal paragangliomas 
The mainstay in the treatment of (extra)-adrenal PGLs is surgery, which can be performed 
conventionally or by laparascopy. To avoid catecholamine- induced complications, patients 
should be treated pre-opertaively with α- and β-receptor blocking mediaction (107). In 
patients with bilateral adrenal PGLs, laparoscopic cortical sparing adrenalectomies are 
considerd by some authors aimed at avoidance of gluco- and mineralcorticoid deficiency. 
Post-operative follow-up with bi-annual measurement of blood pressure and annual 
assement of plasma levels or urinary excreton rates of metanephrines should be performed.  
1.9 Malignant disease 
1.9.1 Head and neck paragangliomas 
Approximately 10% of HNPGLs are malignant. There are no histopathological or 
immunohistochemical features that indicate the malignant potential of the primary tumor 
(108;109). In one patient series malignancy was related to pain, and a younger age at 
presentation (110). Malignant HNPGL have been observed more frequently in vagal PGL 
and in secreting tumors (111;112). Malignant HNPGL are confirmed by the presence of 
local metastases in cervical lymph nodes or systemic metastases (108;109;113). HNPGLs 
can metastasize to bones, lung and liver (113). Malignant HNPGLs occur most frequently 
in patients with SDHB gene mutations (46;49;114). In patients with SDHD gene mutations, 
malignant HNPGLs are rare and estimated to occus in less than 5 % of the patients 
(54;115). To date, only a single malignant HNPGL has been reported in a patient with a 
SDHC gene mutation (116). Because of the high risk of malignancy, patients with SDHB 
gene mutations should be regularly screened with three-body region MRI. This may be 
done with either octreotide-scintigraphy or F-DOPA PET (79;117). The primary 
management of patients with malignant HNPGLs should be directed towards complete 
surgical resection of the primary tumor and regional lymp nodes. Postoperative radiation  
may be beneficial in slowing the progression of residual disease (113). Lee et al. reported a 
5-year relative survival rate of 59.5%, 76.8% for regionally confined carcinoma and 11.8% 
for distant metastases (113). A 5-year survival rate of 71.2% was reported by Manolidis et 
al. was 71.2%; (112).  
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1.9.2 (Extra)-adrenal paragangliomas 
Treatment for malignant (extra)-adrenal PGLs include surgical debulking, pharmacological 
control of catecholamine induced symptoms, external radiation, and systemic antineoplastic 
therapy. There is no effective treatment for malignant (extra)-adrenal PGLs. Surgical 
debulking is widely regarded as the mainstay of palliative therapy in the treatment of 
malignant PGL. Treatment with therapeutic dosis of 
131
I-MIBG or combination 
chemotherapy may induce (partial) responses. External beam irradiation may be usefull in 
the treatment of local tumor complications. Catecholamine induced signs and symptoms 
can be treated with α-receptor blocking medication. Prognosis in confirmed malignant 
PGLs is difficult to predict, but is known to be poor secondary to local recurrence or 
widespread metastases. 5-year survival rates are only 20% to 50%, the outcome is related to 
tumor size (118;119). 
1.10 Genetic testing  
Germline mutations in the mitochondrial complex II genes (SDHB, SDHC, SDHD) cause 
hereditary paragangliomas. Rare reports of HNPGL occur in MEN type 2 and VHL disease 
(6-9).  Because 30% of patients with apparently sporadic HNPGL are affected by a SDHx 
mutation, molecular genetic screening should be performed in all patients with HNPGL. All 
SDH genes should be tested in patients with single HNPGL before the age of 45 years, but 
only SDHB and SDHC would be recommended above this age. The development of a 
single SDHD-related HNPGL in an older patient without familial antecedents is extremely 
rare (120). It is recommendable to screen for mutations in all patients with HNPGL, 
irrespective of clinical indicators of germline mutations. Given the low incidence of these 
patients and the relatively low workload of the genetic screening, the costs of this approach 
should not be too high considering the benefits. The identification of germline mutations is 
of importance because it gives the opportunity for early diagnosis through periodical image 
studies in family members of the affected individual (121). First degree relatives of 
mutations carriers should be screened as well. Genetic classification is essential for 
downstream management of the patients and preemptive management of family members 
(45). Early detection of a familial paraganglioma allows early surgical treatment, reducing 
the complication rate of this operation (48). In some restricted geographic areas specific 
mutations due to a founder effect increase the frequency of hereditary HNPGL. All patients 
from those areas should be screened for those mutations first, before application of 
proposed testing algorithm (15;45;122). The identification of a SDHD or SDHB mutation 
should lead to complete investigations before surgery to detect all paragangliomas and 
metastases (46). The mutation positive carriers need regular clinical follow-up (45;54).  
here is currently no international consensus regarding intervals and specific programs. A 
minimum monitoring program (54) is recommended which comprises of: 1) a careful 
history and physical examination in association with annual measurement of blood pressure 




1.11 Outline of this thesis 
Part I: High prevalence of founder mutations of the succinate dehydrogenase genes in 
the Netherlands 
Worldwide, an estimated 10% to 50% of head and neck paraganglioma cases are hereditary, 
although in the Netherlands this percentage may be higher due to founder mutations. The 
hereditary paraganglioma syndrome can be caused by mutations in genes encoding subunits 
or co-factors of succinate dehydrogenase (SDH), an enzyme complex bound to the inner 
membrane of the mitochondria. In the Netherlands, several founder mutations, 
characterized by a specific DNA haplotype that is common to all carriers of the mutation, 
have been described in SDHB, SDHC and SDHAF2. In chapter 2, we studied mutation 
frequencies of different genes y in 1045 paraganglioma and pheochromocytoma patients 
and their relatives who tested positive for a mutation in SDHB, SDHC, SDHD or SDHAF2. 
Results were obtained from the Leiden University Medical Centre (LUMC), a dedicated 
referral center for paragangliomas and the national referral laboratory for SDH mutations in 
the Netherlands. As almost all Dutch paraganglioma patient samples are analysed in the 
LUMC, the results represent the actual prevalence of mutations in genes encoding subunits 
of the SDH complex in the Netherlands. 
Part II: the measurement and clinical relevance of 3-methoxytyramine excretion in 
HNPGL patients 
Head and neck paragangliomas can be positive for tyrosine hydroxylase, the enzyme which 
converts tyrosine to L- dihydroxyphenylalanine (L-dopa), the precursor of dopamine. This 
observation suggests that even biochemically inactive paragangliomas may have the 
enzymatic ability to synthesize catecholamines. Interestingly, dopamine functions as a 
neurotransmitter in HNPGLs. It is unclear to which extent dopamine production is present 
in HNPGL in general. Dopamine is converted to 3-methoxytyramine by the enzyme 
catechol-O-methyltransferase. Urinary excretion rates of 3-methoxytyramine (3MT) have 
not been assessed in paraganglioma patients. In chapter 3 we studies the prevalence of 
increased urinary 3MT excretion rates in HNPGL patients and the clinical, biochemical and 
radiological characteristics of HNPGL patients with increased 3MT excretion by comparing 
patients with and without increased urinary excretion of 3MT  
It is unknown whether plasma catecholamine levels, including 3MT, are more sensitive 
parameters of biochemical activity of HNPGL than urinary excretion rates. For the 
diagnosis of pheochromocytoma, the measurement of plasma free metanephrine levels is  
the optimal biochemical test with the highest sensitivity and specificity. Therefore, in 
chapter 4 we studied whether plasma free metanephrines and 3MT levels are more 
sensitive tests to detect biochemical activity of HNPGL than urinary excretion rates of 




Part III: A small percentage of head and neck paragangliomas secrete chromogranin 
A 
Chromogranin A (CgA) is a secretory protein from neuroendocrine cells that mediates 
chromaffin granule biogenesis, necessary for catecholamine storage. CgA is secreted from 
neurosecretory vesicles, along with catecholamines. In accordance with these biological 
concepts, plasma CgA is a usefull tumor marker in patients with pheochromocytoma. In 
chapter 5 we evaluated the prevalence of increased CgA levels in patients with hereditary 
HNPGL and identified a possible role of CgA in patients with biochemically silent 
tumors.Part IV: Pheochromocytomas detected by biochemical screening in 
predisposed subjects have a different clinical presentation compared to patients 
detected by signs and symptoms 
Pheochromocytomas are rare neuroendocrine tumors derived from chromaffin tissue within 
the adrenal medulla. In 12-24% of cases of an apparently sporadic presentation, a 
pheochromocytoma is caused germline mutations in the von Hippel-Lindau gene (VHL), 
the RET gene (leading to MEN2), the neurofibromatosis type I gene (NF1) or one of the 
SDH genes encoding for subunits B, D and C of mitochondrial succinate dehydrogenase.  
Sporadic pheochromocytomas are usually identified by signs and symptoms, including 
paroxysms of headache, sweating, palpitations and hypertension resulting from the release 
of catecholamines from the tumor. However, a substantial proportion of patients with 
pheochromocytomas do not have signs and/or symptoms, which carries the risk of 
unexpected life-threatening catecholamine crises. Therefore, the advice is to screen patients 
with a known hereditary predisposition for the development of pheochromocytomas at 
regular intervals by measurement of plasma levels and/or urinary catecholamine excretion 
rates. In chapter 6 we describe the results of a retrospective study comparing the data of 
patients with pheochromocytomas detected by signs and symptoms and of patients with 
pheochromocytomas, detected by biochemical screening in hereditary syndromes. We 
compared signs and symptoms, biochemical parameters, (peri)operative outcome and long-
term results between these groups. 
Part V: Patients with bilateral carotid body tumors are at risk for developing sleep 
disordered breathing 
Most frequently, paragangliomes develop in the carotid bodies, which can be surgically 
removed. These carotid bodies have important peripheral chemoreceptor functions for 
sensing arterial oxygen concentrations and, to a lesser extent, arterial carbon dioxide 
concentrations. Accordingly, bilateral resection of carotid body paragangliomas abolishes 
the ventilatory responsiveness to hypoxia. Moreover, after bilateral resection of carotid 
body paragangliomas, ventilatory CO2 sensitivity decreases, resulting in increased resting 
end-tidal CO2 pressure (PetCO2) values. In turn, these high resting PetCO2 values are 
associated with irregular breathing, periodic breathing and central sleep apnea. Therefore, 
the question arises whether these patients are prone to develop sleep disordered breathing 
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after bilateral resection of carotid body paragangliomas. At present, it is unknown whether 
carotid body paragangliomas per se cause dysfunction of peripheral chemoreceptor 
function and if patients with bilateral carotid body paragangliomas have altered 
chemoreceptor responses. In chapter 7 we evaluated the presence of sleep disordered 
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Abstract 
Context: Mutations in four genes encoding subunits or co-factors of succinate 
dehydrogenase cause hereditary paraganglioma and pheochromocytoma syndromes. 
Mutations in SDHB and SDHD are generally the most common, whereas mutations in 
SDHC and SDHAF2 are far less frequently observed.  
 
Methods: 1045 DNA samples from Dutch paraganglioma and pheochromocytoma patients 
and their relatives were analyzed for mutations of SDHB, SDHC, SDHD or SDHAF2.  
 
Results: Mutations in these genes were identified in 690 cases, 239 of which were index 
cases. The vast majority of mutation carriers had a mutation in SDHD (87.1%). The second 
most commonly affected gene was SDHAF2 (6.7%). Mutations in SDHB were found in 
only 5.9% of samples, whereas SDHC mutations were found in 0.3%. Remarkably, 69.1% 
of all carriers of a mutation in an SDH gene in the Netherlands can be attributed to a single 
founder mutation in SDHD, c.274G>T, p.Asp92Tyr. Moreover, 88.8% of all SDH mutation 
carriers carry one of just six Dutch founder mutations in SDHB, SDHD and SDHAF2.   
 
Conclusion: The dominance of SDHD mutations is unique to the Netherlands, contrasting 
with the higher prevalence of SDHB mutations found elsewhere. In addition, we found that 
most SDH-mutation related paragangliomas-pheochromocytomas in the Netherlands can be 
explained by only 6 founder mutations in SDHAF2, SDHB and SDHD. The findings 
underline the regional differences in the SDH mutation spectrum, differences that should be 
taken into account in the development of effective screening protocols. The results 
















Mutations in genes encoding subunits or co-factors of succinate dehydrogenase (SDH), an 
enzyme complex bound to the inner membrane of the mitochondria, are an important cause 
of hereditary paraganglioma syndrome (1-3). SDH plays an important dual role as complex 
II in the electron transport chain and as an enzyme of the TCA cycle, catalyzing the 
oxidation of succinate to fumarate. It consists of 4 subunits: a flavoprotein (SDHA), and 
iron-sulfur protein (SDHB), which together make up the catalytic domain, and SDHC and 
SDHD, both transmembrane proteins. In addition to the SDHB, SDHC and SDHD genes, 
an additional SDH-related paraganglioma tumor suppressor was recently identified (4). An 
important co-factor in SDH stability and functionality, SDHAF2 resides as a soluble protein 
within the mitochondrial matrix and plays a role in the attachment of the FAD cofactor to 
SDH (5).   
Hereditary paragangliomas in the Netherlands are frequently caused by mutations in the 
SDHD gene, but mutations in SDHAF2, SDHB, and SDHC are also found (4, 6-9). 
Founder mutations in SDHD including the c.274G>T, p.Asp92Tyr mutation and the 
c.416T>C, p.Leu139Pro mutation play a major role in the prevalence of hereditary 
paraganglioma in the Netherlands (8). More recently, two founder mutations in SDHB were 
identified in Dutch paraganglioma and pheochromocytoma families (6, 10). The c.232G>A, 
p.Gly78Arg mutation is the only SDHAF2 mutation found in Dutch paraganglioma 
patients, and all patients share a common ancestor (4). To date, no SDHC-linked 
paraganglioma families have been described in the Netherlands. 
In this study, we describe the frequency of mutations in SDHB, SDHC, SDHD or SDHAF2 
in 1045 paraganglioma and pheochromocytoma patients and their relatives. The results 
were obtained from the Leiden University Medical Center (LUMC), a dedicated referral 
center for paragangliomas and the primary referral laboratory for SDH mutation analysis in 
the Netherlands. As almost all Dutch paraganglioma patient samples are analysed here, the 
results represent the actual prevalence of mutations in genes encoding subunits of the SDH 
complex in the Netherlands. 
 
Materials and methods 
 
Patients  
Peripheral blood leukocyte DNA from paraganglioma and pheochromocytoma patients and 
their relatives were collected from 1990-2009, at the Department of Human Genetics and 
the Laboratory for DNA Diagnostics of the Leiden University Medical Center (LUMC), the 
primary national referral center for SDH mutation scanning. The majority of DNA samples 
from patients and their relatives were sent for genetic analysis only, with only summary 
clinical data. Reason for referral was diagnosis of ‘paraganglioma’, ‘pheochromocytoma’, 
‘chemodectoma’ or ‘glomus tumor’, in all cases. As the nomenclature of paragangliomas is 
not unequivocal and has changed over time, exact data regarding tumor location (i.e., head-
and neck region, adrenal medulla or extra-adrenal) are therefore unavailable for many 
patients, and are not further discussed. Cases were considered to be familial if two or more 
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affected individuals were identified within the same kindred. An index case is defined as 
the initial patient that presented with paraganglioma.  
 
Mutation and deletion screening 
The SDHB, SDHC, and SDHD genes were scanned for the presence of mutations from 
2000-2009. All exonic regions of these genes were tested by direct sequencing using the 
Sanger method on an ABI 3177 Genetic Analyzer, starting with the exons containing the 
known Dutch founder mutations in SDHD followed by exons that had previously been 
found to contain pathogenic mutations in SDHB, SDHC, and SDHD (in that order) in the 
Dutch population. If this analysis was negative, scanning was completed by analyzing the 
remaining exons of these genes. After the identification of large founder mutation-related 
families in the Netherlands, the current strategy is to scan the SDHB, SDHC, and SDHD 
genes as indicated by the clinical phenotype or as requested by the submitting clinician. In 
2007, mutation-negative cases were retrospectively analysed with MLPA for the presence 
of large deletions in SDHB, SDHC, and SDHD. MLPA has been carried out on all 
mutation-negative cases since then, using the P226 MLPA kit (MRC Holland, Amsterdam) 
containing probes for all exons and the promoter of each of these genes (27 different 
probes), according to the manufacturer’s protocol. In cases with a negative SDHB, SDHC 
and SDHD mutation analysis, SDHAF2 was tested, as recently described (5). Informed 





A total of 1045 samples from paraganglioma and/or pheochromocytoma patients and their 
relatives were analyzed for mutations in SDH-related genes. Mutations in SDHB, SDHC, 
SDHD or SDHAF2 were found in 690 cases, 239 of whom were index cases (Table 1). No 
mutations in SDH genes were found in 101 index cases and 254 family members of SDH 
mutation carriers (Table 1). The majority of SDH mutation carriers in the Netherlands carry 
a mutation in SDHD (87.1%), followed by mutations in SDHAF2 (6.7%), SDHB (5.9%) 
and SDHC (0.3%). By far the most prevalent mutation is the c.274G>T, p.Asp92Tyr 
mutation in SDHD, accounting for 69.1% of all SDH mutation carriers (Fig. 1). In all, 
88.8% of the SDH mutation carriers in the Netherlands carried one of six Dutch founder 
mutations in the SDHD, SDHB or SDHAF2 genes (Table 2 and Fig. 1). A total of 340/1045 
cases tested for SDH mutations were index cases. Mutations in SDHAF2, SDHB, SDHC or 
SDHD were identified in 239/340 (70.2%) index cases, most frequently a mutation in 
SDHD (62.1%) (Table 1). The most prevalent mutation among index cases was also the 








Table 1: Mutations in SDHAF2, SDHB, SDHC, and SDHD. 
 
Gene Exon DNA mutation Protein mutation Cases (n) Index cases(n) 
SDHAF2 4 c.232G>A p.Gly78Arg 46 
4 
SDHB 2 c.136C>T p.Arg46X 3 2 
 2 c.141G>A p.Trp47X 1 1 
 3 c.201-4429_287-933del deletion exon 3 5 5 
 3 c.268C>T p.Arg90X 5 1 
 4 c.343C>T p.Arg115X 2 1 
 4 c.423+1G>A Splicesite 22 9 
 6 c.574T>C p.Cys192Arg 1 1 
 6 c.590C>G p.Pro197Arg 1 1 
 7 c.653G>C p.Trp218Ser  1 1 
SDHC 4 c.214C>T p.Arg72Cys 1 
1 
 5 & 6 c.242-241_510+1978del deletion exon 5 & 6 1 
1 
SDHD 
1 & 2 c.1-8828_169+442 del deletion exon 1 & 2 1 1 
















 2 c.169_169+9 del 
TGTATGTTCT 
unknown 4 1 
 3 c.181delG p.Ala61LeufsX25 2 1 
 3 c.208A>G p.Arg70Gly 1 1 
 3 c.209G>T p.Arg70Met 1 1 
 3 c.242C>T p.Pro81Leu 16 8 
 3 c.274G>T p.Asp92Tyr 477 157 
 3 c.279T>G p.Tyr93X 7 1 
 3 c.284T>C p.Leu95Pro 4 2 
 3 c.287dupC p.Ala97fs 1 1 
 4 c.337_340 del GACT p.Asp113MetfsX21 3 1 
 4 c.416T>C p.Leu139Pro 59 30 
 
Table 2: Dutch founder mutations of the SDHAF2, SDHB and SDHD genes. 
Gene Mutation  Protein References 
SDHAF2 c.232G>A p.Gly78Arg Hao 2009 (5), Bayley 2010 (4) 
    
SDHB c.423+1G>A splice site, intron 4 Hes 2010 (10) 
 c.201-4429_287-933del deletion exon 3 Bayley 2009 (6) 
    
SDHD c.274G>T p.Asp92Tyr Baysal 2000 (2) Taschner 2001 (8) 
 c.416T>C p.Leu139Pro Dannenberg 2002 (24), Taschner 2001 (8) 
 
c.284T>C p.Leu95Pro Cremers 2002 (7), Dannenberg 2002 (24), 
Taschner 2001 (8) 




Figure 1: Relative frequencies of Dutch SDH founder mutation carriers. The graph 






The majority of SDH mutation carriers in the Netherlands harbour the c.274G>T, 
p.Asp92Tyr mutation in SDHD. Several very large families residing in the western part of 
the Netherlands are known to carry this mutation, all linked by a strong founder effect (11). 
The second most widespread SDH mutation in the Netherlands is the c.416T>C, 
p.Leu139Pro founder mutation in SDHD, but this mutation accounts for hardly more than 
10% of the number of p.Asp92Tyr mutation carriers, emphasizing the dominant role of the 
former mutation. Compared to the high prevalence of SDHD mutations, SDHB mutations 
are far less common (87.1% vs. 5.9%), but the majority of SDHB mutation carriers also 
harbour known founder mutations, specifically the intron 4 splicesite mutation, 
c.423+1G>A or the exon 3 deletion, c.201-4429_287-933del (6, 9) (Tables 1 and 2).  
The difference in prevalence between SDHB and SDHD mutation carriers may in part be 
attributable to the lower penetrance of SDHB mutations (10, 12-14). Despite their common 
forebears, most patients with a Dutch founder mutation in SDHB present without a family 
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history of paraganglioma, suggesting that many more SDHB mutation carriers await 
discovery (12-16). 
We noted a remarkable 14-fold difference in the number of SDHD and SDHB mutation 
carriers, and even taking only index cases into account, SDHD mutation carriers still 
predominate with a ratio of around 10:1 (Table 1). None of the international studies that 
have reported variation in relative frequencies of SDHB and SDHD mutations in head and 
neck paraganglioma cases have described such a large difference. An recent large Italian 
study identified a 2 fold higher prevalence of SDHD mutations (17), while a broader 
European study showed an approximate 1:1 distribution of SDHB and SDHD mutation 
carriers (13). Other studies have shown a 2.7- 4.5-fold higher frequency of SDHB mutation 
carriers (12, 14). In general, SDHB mutations are more common than SDHD mutations, 
indicating that SDHB mutation carriers in the Netherlands only appear to be scarce due to 
the higher prevalence of SDHD founder mutations.  
Haplotype studies of the most prevalent founder mutations have shown unequivocally that 
mutation carriers share a common haplotype surrounding the mutations, and therefore share 
a common ancestor. The Dutch SDHD mutation, p.Asp92Tyr, is estimated to be 200-960 
years old based on coalescence time calculations, and all known Dutch carriers of the 
SDHAF2 mutation, p.Gly78Arg, share a common haplotype and have also been linked to a 
common ancestor (11, 18).  
In addition to mutations of SDHB and SDHD, we identified 46 carriers of the c.232G>A, 
p.Gly78Arg mutation in SDHAF2. Four large SDHAF2-linked paraganglioma families 
from the South East Netherlands are now known to share a common ancestor, a male, born 
in 1771 and who married three times (19).These families have remained largely in the same 
area and the p.Gly78Arg mutation is a founder mutation in the South East Netherlands, 
accounting for a significant proportion of the paraganglioma cases seen in the region.  
Paraganglioma syndrome due to mutations in SDHC is extremely rare in the Netherlands. 
We have identified only two SDHC mutations, c.242-241_510+1978del and c.214C>T, in 
two patients (0.3%). Like SDHB, SDHC mutations may have been underreported because 
of the often sporadic-like presentation of SDHC-linked paraganglioma syndrome (3, 20). 
The remarkable prevalence of Dutch SDH founder mutations is most probably due to the 
unusual social and demographic history of the Netherlands. Until only a generation ago, 
Dutch society was highly segregated, primarily on the basis of religious differences. This 
segregation affected social, political and cultural life, and was further aided by socio-
economic, geographic, and linguistic factors. These factors limited intermarriage until well 
into the twentieth century, and the creation of genetically isolated populations, facilitating 
the proliferation of Dutch founder mutations, both in SDHD and other disease genes (21). 
The p.Asp92Tyr founder mutation in SDHD shows a strong geographic focus even today 
(8, 11).  
Mutations of SDHB, SDHC, SDHD and SDHAF2 each result in distinct hereditary 
paraganglioma syndromes, with differing modes of inheritance, penetrance, risk of 
pheochromocytoma, and risk of malignant paraganglioma, meaning that prior identification 
of the affected gene is essential to provision of effective genetic counselling to the 
individual patient (13, 14, 20). Several algorithms prioritizing gene-specific mutation 
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testing in paraganglioma patients have been proposed, based on phenotypic characteristics, 
and with the dual objectives of minimizing mutation screening and cost reduction (22, 23). 
Although these algorithms represent a useful starting point for genetic analysis, it is 
doubtful whether the effectiveness and outcome of such algorithms are universally 
applicable, as the a priori chance of finding a mutation in a specific gene differs from 
country to country. Recognition of regional differences in the prevalence of mutations will 
allow the tailoring of genetic screening on the basis of local knowledge. 
The present study shows that the majority of mutations in SDH subunits or co-factors in the 
Netherlands involve SDHD, followed by SDHAF2, SDHB and SDHC, and the majority of 
mutation carriers harbour the Dutch SDHD founder mutation, p.Asp92Tyr. This finding is 
in strong contrast with the extensive genetic heterogeneity found elsewhere and underlines 
the importance of regional differences in the mutation spectrum of genes associated with 
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Context: Patients with head-and-neck paragangliomas (HNPGL) are regularly screened for 
catecholamines excess. The clinical relevance of increased urinary secretion of 3-
methoxytyramine (3MT) is unclear in HNPGL. 
 
Objective: To assess the prevalence and the clinical, biochemical and radiological 
presentation of patients with HNPGL with increased urinary excretion of 3MT.  
 
Patients and Methods: 136 consecutive patients with HNPGL were included and screened 
for catecholamine excess by measurement of 24-hr urinary excretion of (nor)metanephrine, 
(nor)epinephrine, VMA, dopamine and 3MT. In patients with catecholamine excess, 
abdominal/intrathoracic paragangliomas were excluded by 
123
I-MIBG scintigraphy, MRI 
and/or CT. 
 
Results: Urinary 3MT excretion was increased in 31 of the 136 patients (23 %). In 18 of 
these 31 patients this was the only sign of biochemical activity of HNPGL. Dopamine 
excretion was higher in subjects with increased 3-MT excretion (1.62±0.1 µmol/24h vs. 
2.5±0.3 µmol/24h, p<0.01). Of the 136 HNPGL patients, 21 (15%) had excessive excretion 
of at least 1 catecholamine and/or their metabolites when 3MT excretion was not taken into 
account. With the inclusion of patients with excessive 3MT excretion, 39 (29%) had 
excessive catecholamine excretion. Patients with 3MT excess had significantly more 
complaints of palpitations (p<0.01), diaphoresis (p=0.03), collapse (p<0.05) and a higher 
pulse rate (p<0.01). Increased excretion of 3MT was not associated with particular types of 
HNPGL or genotypes.  
 
Conclusions: A substantial number of HNPGL patients have biochemically active tumors, 
reflected in increased excretion of 3MT, associated with increased dopamine excretion. 






Head-and-neck paragangliomas (HNPGL) are rare neuroendocrine tumors derived from 
parasympathetic ganglia, whereas abdominal and thoracic paragangliomas are derived from 
sympathetic ganglia (1). The majority of sympathetic paragangliomas produce 
catecholamines, especially if they are located in the adrenals (pheochromocytomas) (2). 
Although HNPGLs have the potential to produce and secrete catecholamines(3), only a 
minority of these patients (4%) actually have biochemical evidence of catecholamine 
excess (3;4).  
HNPGL can be positive for tyrosine hydroxylase, the enzyme which converts tyrosine to L-
dihydroxyphenylalanine (L-dopa), the precursor of dopamine. This observation suggests 
that even biochemically inactive paragangliomas may have the enzymatic ability to 
synthesize catecholamines (5). Interestingly, dopamine functions as a neurotransmitter in 
HNPGLs (6-8). However, dopamine production or dopamine co-secretion has been 
reported mainly in metastatic extra-adrenal paragangliomas, which has been interpreted to 
be a reflection of dedifferentiation and to be predictive of malignant potential in 
preoperative patients with apparently non-metastatic paragangliomas (9-11). However, 
these data were predominantly reported in tertiary referral centers for malignant 
paragangliomas. Therefore, it is unclear to which extent dopamine production is present in 
HNPGL in general. Dopamine is converted to 3-methoxytyramine (3MT) by the enzyme 
catechol-O-methyltransferase. Eisenhofer et al. showed that plasma free 3MT may be 
useful for identification of paragangliomas that produce predominantly dopamine, whereas 
urinary excretion of dopamine is a relative insensitive and nonspecific marker for dopamine 
secreting tumors (9). Urinary excretion rates of 3MT have not been assessed in 
paraganglioma patients.   
Therefore, the aim of the present study was to assess the prevalence of increased urinary 
3MT excretion in HNPGL patients and to assess the clinical, biochemical and radiological 
characteristics of HNPGL patients with increased 3MT excretion by comparing patients 
with and without increased urinary excretion of 3MT. 
 
Patients and Methods 
 
We evaluated in a cross sectional study the clinical, biochemical and radiological data of all 
consecutive patients with HNPGL who were followed at the outpatient clinic of the Leiden 
University Medical Center, a tertiary referral center for patients with paragangliomas. 
Biochemical screening included the measurement of catecholamine excretion in 24 hour 
urinary samples: (nor)metanephrines, (nor)epinephrine, dopamine and 3-methoxytyramine.  
All patients were investigated at the outpatient clinic according to structured clinical 
protocols, which were standard care. These included questions focused at tumor- and 
catecholamine related signs and symptoms, measurement of blood-pressure in the supine 
position, and after 5 minutes of upright position, in order to screen for orthostatic 
hypotension. Repetitive head-and-neck MRI was performed with intervals of at least 2 
years. Urine was collected during 24 hours in duplicate under strict dietary regulations 
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(patients abstained from pineapple, avocado, bananas, kiwi, nuts, plums, coffee, tea and 
other caffeine containing beverages) and after withdrawal of medication for several weeks 
or after changing antihypertensive medication to doxazosine. In case of excessive 
catecholamine excretion (i.e., any value above the upper reference limit in two urine 
samples), radiological assessment by MIBG-scans and MRI and/or CT scans of thorax and 
abdomen were performed to identify the source of excessive catecholamine production. All 
patients with documented paragangliomas in the abdomen or thorax were excluded in the 
present study, because the interpretation of the biochemical results in relation to HNPGL 
could be confounded by the presence of these other paragangliomas.  
We performed screening for SDH mutations in those HNPGL patients, who agreed to 
genetic testing. Hereditary disease was diagnosed on the basis of the presence of mutations 
of SDHB, SDHC, or SDHD in the patient and/or a family member. 
We screened 156 consecutive HNPGL patients for catecholamine excess, including 
dopamine and 3-methoxytyramine excretion. Nineteen of these 156 patients were excluded 
from the current study because HNPGL had previously been resected and, therefore, these 
patients were without HNPGL at the moment of the current study. One patient with 
elevated 3-methoxytyramine excretion was excluded from the current analyses, because no 
additional radiological assessment was performed to exclude the presence of other 
paragangliomas not related to the head and neck regions. Therefore, the study group 
comprised of 136 patients with HNPGL.  
The study was an evaluation of routine patient care. According to the requirements of 
Dutch law, it was not necessary to obtain permission from the institutional ethical 





Epinephrine, norepinephrine and dopamine excretion in 24 h urine collections were 
quantified by reversed high pressure liquid chromatography (HPLC) equipped with an 
electrochemical detector. Inter- and intra-assay coefficients of variations (CVs) for 
epinephrine were 4.3-9.0% ranging from high to low levels. For norepinephrine these data 
are 2.7-3.6% and for dopamine 3.1-4.8%. Vanillylic mandelic acid (VMA) excretion in 
urine was measured using HPLC with fluorometric detection with inter- and intra-assay 
CVs of 2.4-9.1%. (Nor) metanephrine and 3MT were determined by stable isotope mass 
fragmentography. The CVs f the 3-O-methylated catecholamine metabolites 
(nor)metanephrine and 3MT ranged from 1.7 to 4.2% (12). 
Reference ranges were obtained in healthy volunteers. These values were for 
norepinephrine 0.06-3.40 µmol/24h, epinephrine <0.16 µmol/24h, dopamine 0.46-3.40 
µmol/24h, VMA <30 µmol/24h, metanephrine 33-90 µmol/mol creatinine, normetanephrine 
64-260 µmol/mol creatinine and 3MT 45-197 µmol/mol creatinine (13). SDH mutation 







SPSS for windows version 16.0 (SPSS inc., Chicago, IL) was used for data analysis. 
Results are expressed as means ± standard error (SE), unless specified otherwise. 
Independent sample t-tests and chi-square tests were used to compare patients with and 
without increased urinary excretion of 3MT. The average value of catecholamine excretion 
rates of two urine samples was used for calculation of p values. A p-value <0.05 was 
considered to represent a significant difference. 
Results 
 
Clinical and biochemical data 
All 136 patients had HNPGL, because the presence of HNPGL was an inclusion criterion 
(Table 1). Urinary excretion of 3MT excretion was increased in 31 patients (23 %) (Table 
2). In these patients the mean excretion of dopamine was also significantly increased 
(p<0.01) compared to the subjects without increased 3MT excretion. 
In the 31 patients with increased 3MT excretion, 13 patients (42%) also had increased 24-
hour urinary excretion of other catecholamines. One patient also had elevated urinary 
excretion of norepinephrine, 3 patients of VMA, 4 patients of metanephrine, 6 patients of 
normetanephrine and 5 patients of dopamine (Table 2).   
Eight of the 105 patients with normal 3MT excretion (8%) had increased urinary excretion 
of other catecholamines. Four patients had elevated excretion of VMA, 3 of metanephrine, 
1 of normetanephrine and 1 of dopamine. 
When the 3MT results were excluded from the analysis, 21 of the 136 patients (15%) had 
excessive secretion of 1 or more catecholamines and/or their metabolites. When increased 
excretion of 3MT was taken into account, 39 patients had excessive excretion of 
catecholamines (29%). In other words, these data indicate that 18 patients had increased 
excretion of 3-methoxytyramine without excessive excretion of other catecholamines. 
 
Clinical characteristics of patients with and without increased 3-methoxytyramine 
excretion (Table 3) 
Patients with increased excretion of 3MT had more signs and symptoms (n=24, 80%) 
compared to the patients with normal 3-methoxytyramine excretion (n=59, 56%, p=0.01), 
including more complaints of palpitations (p<0.01), diaphoresis (p<0.03), collapse (p<0.05) 
and a higher pulse rate (p=0.01). In both patient groups hypertension was the most common 
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Table 1: Clinical characteristics of 137 HNPGL patients with and without excessive 
urinary 3-methoxytyramine excretion 
 
Urinary 3-methoxytyramine excretion 
               Normal                           Elevated  
 
 
Patient characteristics N=105 N=31 p-value 
Age (yrs) 49.3 ± 1.3 49.9 ± 2.2 0.82 
Gender N (%) 
        Men 









BMI (kg/m2)  24.6 ± 0.37 26.1 ± 1.4 0.31 
Systolic BP (mm Hg) 133.6 ± 1.9 139.1 ± 2.9 0.16 
Diastolic BP (mmHg) 80.2 ± 1.0 83.3 ± 2.0 0.16 
Heart Ratio (beats/min) 71.3 ± 0.9 77.6 ± 1.9 <0.01 
Type of glomustumor 
       Caroticum 
       Jugulare 
       Vagale 
       Jugulotympanicum 



















Number of HNPGL 
       1 
       2 
       3 

















No of patients with genetic analysis 
      SDHD 
       SDHD* fam 
       SDHD total 
       SDHB 
       SDHB** fam 
       SDHB total 

























       No mutation found 6 (6%) 3 (10%)  
 
* SDHD mutation characterized in family member; ** SDHB mutation characterized in family member. 
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Table 2: Urinary catecholamine excretion in 137 HNPGL patients, with and without 
increased 3-methoxytyramine excretion 
             Urinary 3-methoxytyramine excretion     
 normal elevated normal elevated  
catecholamines N tested pos N tested pos Mean ± SE Mean ± SE  p-value 
Epinephrine  
(µmol/24 h) 
0  0 0.02 ± 0.0 0.02 ± 0.0 0.45 
Norepinephrine 
(µmol/24 h) 
0 1 (3 %) 0.34 ± 0.1 0.55 ± 0.2 0.21 
Dopamine 
(µmol/24 h) 
1 (1 %) 5 (16 %) 1.62 ± 0.1 2.5 ± 0.3 <0.01 
VMA 
(µmol/24 h) 
4 (4 %) 3 (10 %) 21.7 ± 0.6 24.4 ± 2.2 0.25 
Metanephrine 
(µmol/molkre) 
3 (3 %) 4 (13 %) 52.1 ± 2.0 52.1 ± 2.0 0.04 
Normetanephrine 
(µmol/molkre) 
1 (1 %) 6 (19 %) 140 ± 5.0 300 ± 72 0.03 
3M-tyramine 
(µmol/molkre) 
0 31 (100 %) 107 ± 6.0 971 ± 219 <0.001 
 
A patient is considered to be positive for the urinary excretion of a specific catecholamine or metabolite if the 
value is above the reference limit in two consecutive urine samples.  
 
Radiological and MIBG assessment (table 1) 
 
Radiological assessment of head and neck 
Localization studies of the head and neck region were performed in all patients. 
Radiological evaluation of the head and neck region was performed by MRI in 95% of 
patients, and by CT-scanning in 6% of the patients. We refer to Table 1 for further details 
of the type and number of HNPGL. 
There was no significant difference in the number and types of HNPGL between the two 
groups.  
Most patients with HNPGL (n=78) had multiple HNPGL, which prohibited the 
identification of a culprit lesion of 3-methoxytyramine excretion. We identified 58 patients 
with only a single HNPGL, 49 patients with normal 24h urinary excretion rates of 3MT,and 
9 patients with increased excretion rates of  3MT . Compared to patients with normal 24h 
urinary excretion rates of 3MT , the maximal tumor diameter tended to be higher in patients 
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with increased 24 h rates of 3MT  excretion (2.8 ± 0.3 vs. 4.2 ± 0.7cm (mean diameter ± 
SE, p = 0.08).  
Table 3: Signs and symptoms of 137 HNPGL patients, with and without increased 3-
methoxytyramine excretion 
                   Urinary 3-methoxytyramine excretion    
                   normal elevated  
 n (%) n (%) p-value 
Symptoms/ signs 59 (56%) 24 (80%) 0.01 
Dizziness 6 (6%) 4 (13%) 0.23 
Tinnitus 18 (17%) 4 (13%) 0.78 
Hearing loss 23 (22%) 9 (30%) 0.47 
Hoarseness 8 (8%) 5 (17%) 0.16 
Difficulty swallowing 8 (8%) 3 (10%) 0.71 
Palpitations 3 (3%) 6 (20%) <0.01 
Diaphoresis 4 (4%) 5 (17%) 0.03 
Headache 4 (4%) 1 (3%) 1.00 
Flushes 3 (3%) 0 1.00 
Nausea 0 0 - 
Vomiting 0 0 - 
Pharyngeal fullness 3 (3%) 0 1.00 
Cranial nerve palsy 3 (3%) 3 (10%) 0.12 
Collapse 0 2 (7%) <0.05 
Hypertension (>140/90) mmHg ) 25 (24%) 11 (39%) 0.13 
Hypotension (<90/ 60 mmHg) 0 1 (4%) 0.22 
 
Additional radiological analysis 
In the 31 patients with increased 3MT excretion, an MIBG scan was performed in 27 
patients (87%). In 11 of these 27 patients (41%), the MIBG scan showed increased uptake 
in the head and neck region, but not elsewhere in the body. In addition, in 13 of these 31 
patients abdominal/ thoracic paragangliomas were excluded by MRI, in 11 patients 
abdominal paragangliomas were excluded by MRI, in 1 patient abdominal paragangliomas 
were excluded by CT, in 3 patients abdominal and thoracic paragangliomas were excluded 
by MRI, in 1 patient abdominal paragangliomas were excluded by MRI and thoracal 
paragangliomas were excluded by CT. In 2 patients paragangliomas were excluded only by 
MIBG-scintigraphy. In the 105 patients with normal excretion of 3-methoxytyramine, a 
MIBG scan was performed in 36 patients (34%). In 18 of these 36 patients (50%), the 
MIBG scan showed increased uptake in the head and neck region, but not elsewhere in the 
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body. In the 8 patients with increased urinary catecholamine excretion, abdominal and/or 




This study documents that 23 % of HNPGL patients have increased urinary excretion of 
3MT. When all biochemical data were included, 29% of all HNGPL patients had increased 
excretion of catecholamines and/or their products. In some of the patients with increased 
excretion of 3MT, the excretion of other catecholamines or their metabolites was not 
increased, indicating that the biochemical activity of HNPGL was only reflected in 
increased excretion of the 3MT. The clinical manifestations in patients with increased 3MT  
excretion were different compared to patients with normal excretion of 3MT. Patients with 
increased excretion of 3MT suffered more frequently from palpitations, diaphoresis, 
collapse and had a higher pulse rate. Therefore, our study results indicate that the 
prevalence of  biochemically active HNPGL is much higher than hitherto appreciated in 
studies which did not include urinary 3MT measurements (4). 
Patients with HNPGL frequently have multifocal tumors, which was also apparent in the 
present study. Consequently, it is difficult to identify the culprit lesion of 3MT excretion. 
Nonetheless, it is evident from the present study that each type of head and neck 
paraganglioma can be associated with increased 3MT excretion. 
Urinary dopamine is primarily derived from renal extraction and decarboxylation of 
circulating DOPA, the precursor of dopamine. In addition, HNPGL that produce dopamine 
as the main catecholamine, can be identified by 24 hour urinary excretion of 3MT, and this 
O-methylated metabolite of dopamine provides a better marker for these tumors than does 
urinary excretion of dopamine. Eisenhofer et al. reported in patients with adrenal and extra-
adrenal paragangliomas that plasma methoxytyramine was a better marker than urinary 
excretion of dopamine (9). We found that only part of the HNPGL patients with increased 
urinary excretion of 3MT also had increased urinary dopamine excretion. Therefore, 
urinary 3MT excretion is more sensitive in discovering dopamine-producing HNPGL than 
urinary dopamine excretion. Additional studies comparing plasma dopamine and 3MT 
levels and 24 hour urinary excretion of dopamine and 3MT are needed to assess the 
diagnostic sensitivity and benefits of these measurements in patients with HNPGL. 
Only one previous study evaluated catecholamine production by HNPGL, which reported a 
prevalence of 4% of biochemically active HNPGL (4). Catecholamine excess was defined 
in that study by “increased excretion of one or more catecholamines or their metabolites 
above the cut-off point in at least one 24 hour urinary sample”, whereas in our study a more 
stringent criterion of catecholamine excess in two 24 hour urinary samples was required. 
Moreover, in that study not every patient with HNPGL was screened for catecholamine 
excess. In addition, measurement of urinary excretion of VMA was not included in their 
biochemical screening. In our study, exclusion of the VMA results reduced the incidence of 
catecholamine excess to 12% of the 136 patients. Therefore, it is very likely that the 
prevalence of biochemically active HNPGL is much higher than hitherto appreciated. The 
biochemical proof of HNPGL associated catecholamine excess is normalization of 
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catecholamine excess after resection of HNPGL. However, since most of HNPGL grow 
very slowly (16), and operative resection is accompanied by considerable morbidity (17), 
for the majority of patients a wait-and-scan strategy is advised. Nonetheless, our study 
shows that the incidence of catecholamine secreting HNPGL is higher than currently 
appreciated. 
Although dopamine secreting paragangliomas are often asymptomatic (9), excessive 
excretion of dopamine can cause complaints of nausea, vomiting, flushing and orthostatic 
hypotension (18;19). We observed that the clinical manifestations in patients with increased 
3MT excretion were different compared to those in patients with normal excretion of 3MT. 
Moreover, there was no difference in the presence of hyper- or hypotension between 
patients with and without increased excretion of 3MT.  
Dopamine production or co-secretion has been interpreted as a sign of dedifferentiation and 
to be predictive of malignant potential (9-11). Our cohort consists of patients with only 
benign HNPGL, either sporadic or as a part of a familial syndrome caused by SDHB or 
SDHD mutations. There were no differences in the prevalence of mutations in these two 
genes between HNPGL patients with and without increased 3MT excretion. In addition, our 
results show that increased excretion of 3MT, and the associated increase in dopamine 
excretion, is not associated with malignant paragangliomas.  
In conclusion, a relatively large number of patients with HNPGL have increased excretion 
of 3MT. Urinary 3MT excretion is a more sensitive marker than urinary dopamine 
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Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher 
number of biochemically active HNPGL than 24 h urinary excretion rates of 
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Context: A substantial number of patients with head and neck paragangliomas (HNPGL) 
have biochemically active tumors, evidenced by increased urinary excretion of 
catecholamines and metabolites, including 3-methoxytyramine (3MT). It is unclear whether 
plasma levels of these parameters are more sensitive to detect biochemical activity in 
HNPGL patients than urinary excretion rates.  
 
Objective: To compare plasma free levels versus urinary excretion rates of deconjugated 
3MT and combined metanephrines in patients with HNPGL. 
 
Patients and Methods: We included 124 consecutive patients with HNPGL for screening 
for catecholamine excess by measurement of 24-hr urinary excretion rates of deconjugated 
(nor)metanephrine, (nor)epinephrine, dopamine, vanillylmandelic acid, 3MT and plasma 
free levels of (nor)metanephrine and 3MT.  
 
Results: Plasma free 3MT levels were increased in 35 of the 124 patients (28%), whereas 
24-h urinary excretion of deconjugated 3MT was increased in 30 patients (24%) (p=0.13). 
Plasma free metanephrine (MN) levels were increased in 7 patients (6%), urinary 
deconjugated metanephrine levels in 6 (5%) (p=1.00). Plasma free normetanephrine (NMN) 
levels were increased in 7 patients (6%), and 5 patients had increased urinary excretion of 
deconjugated normetanephrine (4%) (p=0.69). Plasma free combined metanephrine levels 
(NMN, MN, 3MT) were increased in 41 patients (33%), whereas 24-h urinary excretion 
rates of deconjugated combined metanephrines was increased in 33 patients (27%, p<0.05).  
 
Conclusions: The combined levels of free metanephrines and free 3MT in plasma indicate 

















Head and neck paragangliomas (HNPGL) are rare neuroendocrine tumors derived from 
parasympathic ganglia (1). Some patients with HNPGL have biochemically active HNPGL, 
evidenced by increased urinary excretion rates of catecholamines and their metabolites (2-
4). The majority of those patients have increased urinary excretion rates of 3-
methoxytyramine (3MT), the 3-O-methylated metabolite of dopamine (3).  
It is presently unknown whether plasma free concentrations of 3-O-methylated metabolites 
of catecholamines, including 3MT, are more sensitive parameters of biochemical activity of 
HNPGL than urinary excretion rates of catecholamines or deconjugated 3-O-methylated 
metabolites. For the diagnosis of pheochromocytoma, the measurement of plasma free 
metanephrine concentrations is the optimal biochemical test with the highest sensitivity and 
specificity (5-8). Therefore, the aim of the present study was to assess whether plasma 
levels of free metanephrines and 3MT are more sensitive parameters of biochemical 
activity of HNPGL than urinary excretion rates of free catecholamines and their 
deconjugated metabolites. 
 
Patients and Methods 
 
We performed a cross sectional study of 130 consecutive patients with HNPGL who were 
followed at the outpatient clinic of the Leiden University Medical Center, a tertiary referral 
center for patients with paragangliomas.  For this purpose clinical, biochemical and 
radiological data of all consecutive patients with HNPGL were evaluated. All patients were 
investigated at the outpatient clinic according to structured standard clinical protocols. 
These included questions focused at tumor and catecholamine related signs and symptoms, 
measurement of blood-pressure in the supine position, and after 5 minutes of upright 
position, in order to screen for orthostatic hypotension. In all patients head-and-neck MRI 
were performed or had been performed within the previous 2 years.  
Urine was collected during 24 hours in duplicate under strict dietary regulations (patients 
abstained from pineapple, avocado, bananas, kiwi, nuts, plums, coffee, tea and other 
caffeine containing beverages) and after withdrawal of medication for at least one week or 
after changing antihypertensive medication to doxazosine for several weeks. In order to 
ascertain adequacy of urinary collection, 24-hour urinary creatinine excretion rates were 
measured as well. Blood samples were drawn after the second day of urine collection in the 
postabsorptive state. Blood samples were drawn from an intravenous catheter inserted into 
a forearm vein after 30 minutes of rest in the supine position and collected in cold, 
glutathione containing vacutainers. All blood samples were centrifuged immediately at 
3000 rpm for 10 min at 4 ºC. Plasma samples were stored at -80 ºC until analyses.  
Biochemical screening included the measurement of urinary excretion rates of 
deconjugated (nor)metanephrine, free (nor)epinephrine, dopamine and deconjugated 3MT 
excretion in two 24-hour urinary samples, and the measurement of plasma free 
(nor)metanephrines and 3MT concentrations. 
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In case of excessive catecholamine or metabolite excretion (i.e., any value above the upper 
reference limit in two urine samples or in the plasma sample), radiological assessment by 
MIBG-scans and MRI and/or CT scans of thorax and abdomen were performed to identify 
the source of excessive catecholamine production. All patients with documented 
paragangliomas in the abdomen or thorax were excluded in the present study, because the 
interpretation of the biochemical results in relation to HNPGL could be confounded by the 
presence of these other paragangliomas.  
We performed screening for succinate dehydrogenase (SDH) mutations in those HNPGL 
patients, who agreed upon genetic testing. Hereditary disease was diagnosed if mutations in 
the SDHB, SDHC, or SDHD genes were documented in the HNPGL patient and/or a 
family member. 
We screened 130 consecutive HNPGL patients for catecholamine excess. Four patients 
with catecholamine excess were excluded from the current analyses, because no additional 
radiological assessment was performed to exclude the presence of other paragangliomas not 
related to the head and neck regions. Two patients were excluded because they were 
diagnosed with a pheochromocytoma. Therefore, the study group comprised 124 patients 
with HNPGL.  
The study was an evaluation of routine patient care. According to the requirements of 
Dutch law, it was not necessary to obtain permission from the institutional ethical 





Free Epinephrine, norepinephrine and dopamine excretion rates in 24 h urine collections 
were quantified by reversed phase high pressure liquid chromatography (HPLC) with 
electrochemical detection. Inter- and intra-assay coefficients of variations CVs for 
epinephrine were 4.3-9.0% ranging from low to high concentrations. For norepinephrine 
these data were 2.7-3.6% and for dopamine 3.1-4.8%. Vanillylmandelic acid (VMA) 
excretion in urine was measured using HPLC with fluorometric detection with inter- and 
intra-assay CVs of 2.4-9.1%. Urinary deconjugated (nor)metanephrine and 3MT were 
determined by isotope dilution gas chromatography with mass spectrometric detection. The 
CVs of the 3-O-methylated catecholamine metabolites ((nor)metanephrine and 3MT) 
ranged from 1.7-4.2% (9). Plasma free metanephrines were determined by automated in-
line solid phase extraction and isotope dilution liquid chromatography with mass 
spectrometric detection (11). Reference ranges were obtained in healthy volunteers. These 
values were for urinary excretion: free norepinephrine 0.06-0.47 µmol/24h, epinephrine 
<0.16 µmol/24h, and dopamine 0.46-3.40 µmol/24h, VMA <30 µmol/24h (deconjugated), 
metanephrine (deconjugated) 33-99 µmol/mol creatinine, normetanephrine (deconjugated) 
64-260 µmol/mol creatinine and 3MT (deconjugated) 45-197 µmol/mol creatinine (10). The 
reference intervals for plasma free metanephrines were determined using blood samples 
collected in the supine position from 115 volunteers (57 males, 58 females; age range, 36-
81 years; median age, 55 years) (11) The reference ranges for plasma free metanephrines 
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were: metanephrine 0.07- 0.33 nmol/L, normetanephrine 0.23-1.07 nmol/L and 3MT <0.17 
nmol/L. SDH mutation analysis was performed by restriction digestion as described by 




SPSS for windows version 16.0 (SPSS inc., Chicago, IL) was used for data analysis. 
Results are expressed as means ± standard error (SE), unless specified otherwise. Test 
sensitivity was calculated from the patients with a positive test result divided by the total 
number of patients tested. Test sensitivities were compared using the McNemar test. The 
average value of catecholamine and metabolite excretion rates of two urine samples was 





Clinical characteristics (Table 1) 
The study group comprised 124 patients with HNPGL. Mean age of the patients was 49 
years (range 13-77 years). Fifty-five patients (44%) had a single head and neck 
paraganglioma, whereas 69 patients (56%) had multiple head and neck paragangliomas. 
Paragangliomas occurred most frequently in the glomus caroticum (70%). Fifty-one 
patients (41%) had a glomus vagale tumor, 21 (17%) a glomus jugulotympanicum tumor, 
13 (11%) a glomus jugulare tumor and 12 (10%) a glomus tympanicum tumor.  
Genetic testing for SDHx mutations was performed in 111 of the 124 patients with HNPGL 
(90%). In 95 patients mutations were found (86 SDHD, 8 SDHB and 1 SDHC), whereas in 
16 patients no mutation was found. 
 
Biochemical characteristics (Table 2) 
Forty-six patients (37%) had biochemically active HNPGL, evidenced by increased plasma 
concentrations of free (nor)metanephrine, 3MT and/or increased 24 hour urinary 
concentrations of free catecholamines, and deconjugated metabolites, including 3MT. 
There was no difference between the number of subjects with increased plasma free 3MT 
concentrations compared to the number of subjects with increased urinary excretion rates of 
deconjugated 3MT (n=35 vs. n=30, 28% vs. 24%, p=0.13). Urinary deconjugated 
metanephrine excretion rates were increased in 8% (10 of 124 patients), which in 
combination with the patients with increased urinary deconjugated 3MT concentration, 
increased the number of patients with biochemically active HNPGL to 27% (33 of 124 
patients). Eleven patients (9%) had increased urinary excretion rates of VMA. Increased 
urinary excretion rates of free catecholamines (adrenaline, noradrenaline, or dopamine) 
were present in 10% of the patients (12 of 124 patients). Increased urinary excretion rates 
of combined metanephrines in combination with catecholamines were present in 28% of the 
patients (35 of 124 patients). 
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Plasma free (nor)metanephrine concentrations were increased in 11% of the patients (14 of 
124 patients). The addition of plasma free 3MT levels to these measurements increased the 
portion of patients with evidence of biochemically active HNPGL to 33% (41 of 124 
patients). The number of HNPGL patients with increased plasma free metanephrine levels 
was not significantly different  from the number of patients with increased 24h urinary 
excretion rates of deconjugated metanephrines (11% vs. 8%, p=0.34). Increased plasma free 
metanephrine (MN, NMN) concentrations in combination with increased plasma free 3MT 
levels were present in significantly more HNPGL subjects than increased urinary excretion 
rates of combined metanephrines (MN, NMN) including 3MT (33% vs. 27%, p<0.05).  
Nine patients tested negative with urinary screening of catecholamine excretion rates but 
positive with screening of plasma metanephrine levels. Of these patients 6 had increased 
plasma free 3MT levels, 2 had increased plasma free metanephrine levels and 1 had 
increased plasma free normetanephrine levels.  
 
Catecholamine and metabolite excretion and tumor load  
We identified 55 patients with only a single HNPGL with a mean tumor diameter of 3.3 cm 
(range 0.3-9.7 cm). In those patients there was a weak positive correlation between tumor 
diameters and plasma concentrations of free 3MT (r=0.30, p=0.04), and the combined 
plasma concentrations of free metanephrine, normetanephrine and 3MT (r=0.35, p=0.02). 
There were also weak correlations between tumor diameters and mean urinary excretion 
rates of deconjugated normetanephrine (r=0.40, p<0.01), VMA (r=0.32, p=0.03), dopamine 
(r=0.40, p<0.01), the combined excretion rates of deconjugated metanephrine and 
normetanephrine (r=0.40, p<0.01), the combined excretion rates of deconjugated 
(nor)metanephrine and 3MT (r=0.43, p<0.01) and the mean excretion rate of 
catecholamines (r=0.37, p=0.01). There was no correlation between the number of HNPGL 
and plasma free metanephrine levels, mean urinary excretion rates of deconjugated 
metanephrines and catecholamines. 
 
Catecholamine and metabolite excretion, age, BMI and gender  
Stepwise linear regression analysis was performed in a model including age, gender and 
BMI as independent variables and plasma free metanephrine, normetanephrine and 3MT 
levels as dependant variables. We identified age (β=0.35, p<0.001), BMI (β=-0.29, 
p<0.001) and gender (β=0.35, p<0.001) as independent predictors of plasma free 
metanephrine levels. The patients with increased plasma free metanephrine levels were 
significantly older compared to patients with normal levels (48.0±1.2 vs. 61.5±3.7 yrs, 
p<0.01). Men had significantly higher plasma free metanephrine levels compared to women 
(0.21±0.0 vs. 0.15±0.0, p<0.001).  
For plasma levels of free normetanephrine there was no relation with age (β=0.09, p=0.35), 
BMI (β=0.11, p=0.26) and gender (β=0.09, p=0.35). There was a relation between age (β 





Table 1: Clinical characteristics of 124 patients with head and neck paragangliomas 
(HNPGL). 
 All patients 
with HNPGL 
   N= 124 
Hereditary 
HNPGL 
   N= 95 
Sporadic 
HNPGL 
  N= 16 
Patient characteristics    
Age (yr) 49 ± 1 47 ± 1 58 ± 3 
Gender N (%) 
        Men 










Type of glomus tumor N (%) 
       Caroticum 
        Vagale 
        Jugulare  
       Jugulotympanicum 



















No. of HNPGL N (%) 
       1 










No. of patients with genetic analysis  
       SDHD 
       SDHB 
       SDHC 












The results of this study show that one third of HNPGL patients have biochemically active 
HNPGL. The combined plasma concentrations of free metanephrines and 3MT indicate a 
higher proportion of patients with biochemically active HNPGL than 24 h urinary excretion 
rates of deconjugated metanephrines and 3MT. In addition, the current data indicate that in 
HNPGL patients, plasma free 3MT concentrations and urinary excretion rates of 
deconjugated 3MT do not indentify significantly different numbers of subjects with 
biochemically active HNPGL. 
HNPGL have the ability to produce and secrete catecholamines (2;3). Biochemically active 
paragangliomas are identified by the measurement of plasma (nor)metanephrine and 3MT 
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concentrations and 24h urinary excretion rates of free catecholamines and their 
deconjugated metabolites (6;14). The measurements of urinary excretion rates of 
catecholamine metabolites (i.e., metanephrine and normetanephrine) and especially plasma 
levels of catecholamines and their metabolites are recommended for the biochemical 
screening of pheochromocytoma because of their 
high diagnostic sensitivity and specificity (7). However, the majority of patients with 
biochemically active HNPGL secrete 3MT, which is a metabolite of dopamine. Therefore, 
the measurement of this metabolite should be included if biochemical activity of HNPGL in 
general is assessed. Three-methoxytyramine can be measured in urine and plasma by 
HPLC-tandem mass spectrometric detection (XLC-MS/MS) (11). The present study 
indicates that the assessment of plasma free 3MT levels does not add to the measurement of 
urinary excretion rates of deconjugated 3MT.   
 
Table 2: Plasma metanephrine levels and mean urinary excretion rates of catecholamines, 
VMA and metanephrines in 124 HNPGL patients. 
 Mean (range) N tested positive 
Plasma 
   Normetanephrine                            (nmol/L) 
   Metanephrine                                  (nmol/L) 
   3-methoxytyramine                        (nmol/L) 
   MN + NMN                                    (nmol/L) 














   Normetanephrine                            (µmol/mol creatinine) 
   Metanephrine                                  (µmol/mol creatinine) 
   3-Methoxytyramine                        (µmol/mol creatinine) 
   MN + NMN                                    (µmol/mol creatinine) 
   MN + NMN + 3MT                       (µmol/mol creatinine) 
   Adrenaline                                      (µmol/24 h) 
   Noradrenaline                                 (µmol/24 h) 
   Dopamine                                       (µmol/24 h) 
   Catecholamines                              (µmol/24 h) 
   VMA                                              (µmol/24 h) 

























*indicates a significant difference in test sensitivity between urine and plasma. 




As patients with HNPGL have the ability to (co)secrete noradrenaline (15-17), this 
catecholamine and its metabolite normetanephrine should be measured as well. Combining 
the results of free metanephrines and 3MT in plasma resulted in a slightly, but significantly, 
higher number of patients with biochemically active HNPGL compared to the combined 
results of urinary excretion rates. 
Consumption of catecholamine rich food products can result in substantial increases in 
urinary excretion rates of deconjugated normetanephrine and 3MT, and to a lesser extend in 
plasma free 3MT levels. Therefore, dietary restrictions are indicated prior to collection of 
blood for measurements of plasma free 3MT levels, and urinary excretion rates of 
deconjugated normetanephrine and 3MT (18). Although patients in our study collected 
urine during 48 hour under strict dietary regulations, we can not exclude potential 
confounding effects of the diet. In contrast, the measurements of plasma free metanephrine 
concentrations are not influenced by the confounding effects of dietary components, this 
contributes to the highest sensitivity of plasma levels compared to the measurement of 
urinary excretion rates of metanephrine (18;19). In accordance, plasma free metanephrines 
(MN, NMN, 3MT) levels were increased in a higher percentage of HNPGL patients 
compared to urinary excretion rates of metanephrines. Our findings are in agreement with 
the observations in patients with pheochromocytomas (6-8). Lenders et al. reported a test 
sensitivity of 97% of plasma free metanephrines versus only 60% of urinary combined 
metanephrines in patients with hereditary pheochromocytomas and 99% of plasma 
metanephrine levels versus 88% in urinary excretion rates in patients with sporadic 
pheochromocytomas.  
In conclusion, one third of HNPGL patients have biochemically active HNPGL. The 
combined assessment of plasma concentrations of free metanephrines and 3MT detect a 
higher number of biochemically active HNPGL than the measurement of 24 h urinary 
excretion rates of combined metanephrines and 3MT. In addition, the current data indicate 
that in HNPGL patients urinary excretion rates of deconjugated 3MT and plasma free 3MT 





















 1  DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organisation classification of tumors of 
endocrine organs.  2004.  Oxford, UK: Oxford University Press.  
 2 Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF, Jr. 2001 
Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol 
Metab 86:5210-5216 
 3  van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, Smit JW, Romijn JA, 
Corssmit EP 2010 Increased urinary excretion of 3-methoxytyramine in patients with head and neck 
paragangliomas. J Clin Endocrinol Metab 95:209-214 
 4  Zak FG, Lawson W. The paraganglionic chemoreceptor system. [1st ed. Springer-Verlag New York Inc.]. 
1982.  
 5  Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR 1999 Plasma 
normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and 
multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879 
 6  Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, 
Eisenhofer G 1995 Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 
123:101-109 
 7  Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, 
Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287:1427-
1434 
 8  Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. 2003 A comparison of biochemical tests for 
pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination 
of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558 
 9  Kema IP, Meiborg G, Nagel GT, Stob GJ, Muskiet FA 1993 Isotope dilution ammonia chemical 
ionization mass fragmentographic analysis of urinary 3-O-methylated catecholamine metabolites. Rapid 
sample clean-up by derivatization and extraction of lyophilized samples. J Chromatogr 617:181-189 
 10  Willemsen JJ, Ross HA, Wolthers BG, Sweep CG, Kema IP 2001 Evaluation of specific high-
performance liquid-chromatographic determinations of urinary metanephrine and normetanephrine by 
comparison with isotope dilution mass spectrometry. Ann Clin Biochem 38:722-730 
 11  de Jong WH, Graham KS, van der Molen JC, Links TP, Morris MR, Ross HA, de Vries EG, Kema IP 
2007 Plasma free metanephrine measurement using automated online solid-phase extraction HPLC 
tandem mass spectrometry. Clin Chem 53:1684-1693 
 12  Bayley JP, van M, I, Weiss MM, Jansen JC, Oomen PH, Menko FH, Pasini B, Ferrando B, Wong N, 
Alpert LC, Williams R, Blair E, Devilee P, Taschner PE 2006 Mutation analysis of SDHB and SDHC: 
novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or 
pheochromocytoma. BMC Med Genet 7:1 
 13  Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Brocker-Vriends AH, van Der Mey AG, 
van Ommen GJ, Cornelisse CJ, Devilee P 2001 Nearly all hereditary paragangliomas in the Netherlands 
are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer 31:274-281 
 14  Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak K 2005 
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma 
methoxytyramine. J Clin Endocrinol Metab 90:2068-2075 
 15  Hall FT, Perez-Ordonez B, Mackenzie RG, Gilbert RW 2003 Does Catecholamine Secretion from Head 
and Neck Paragangliomas Respond to Radiotherapy? Case Report and Literature Review. Skull Base 
13:229-234 
 16  Havekes B, van der Klaauw AA, Weiss MM, Jansen JC, van Der Mey AG, Vriends AH, Bonsing BA, 
Romijn JA, Corssmit EP 2009 Pheochromocytomas and extra-adrenal paragangliomas detected by 
screening in patients with SDHD-associated head-and-neck paragangliomas. Endocr Relat Cancer 16:527-
536 
 17  van Houtum WH, Corssmit EP, Douwes Dekker PB, Jansen JC, van Der Mey AG, Brocker-Vriends AH, 
Taschner PE, Losekoot M, Frolich M, Stokkel MP, Cornelisse CJ, Romijn JA 2005 Increased prevalence 
Chapter 4 
68 
of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked 
head and neck paragangliomas. Eur J Endocrinol 152:87-94 
 18  de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP 2009 Dietary influences on 
plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin 
Endocrinol Metab 94:2841-2849 
 19  Eisenhofer G, Coughtrie MW, Goldstein DS 1999 Dopamine sulphate: an enigma resolved. Clin Exp 






Plasma chromogranin A levels are increased in a small portion of patients 












Departments of Endocrinology and Metabolic Diseases, Leiden University Medical 
Center, Leiden, the Netherlands 
2
Department of Laboratory Medicine, University Medical Center Groningen, University of 
Groningen, the Netherlands 
 
Clincal Endocrinology 2011 Feb;74 (2):160-165 
 
 




Context: The majority of patients with head and neck paragangliomas (HNPGL) have 
biochemically silent tumors. Chromogranin A (CgA) is a tumor marker for neuroendocrine 
tumors. 
 
Objective: To assess the role of CgA as a tumor marker in patients with hereditary 
HNPGL. 
 
Patients and Methods: We included 95 consecutive patients with hereditary HNPGL for 
screening of plasma CgA levels and catecholamine excess by measurement of 24-hour 
urinary excretion of (nor)metanephrine, (nor)epinephrine, VMA, dopamine and 3-
methoxytyramine. In all patients with catecholamine excess, abdominal/intrathoracic 
paragangliomas were excluded by 
123
I-MIBG scintigraphy, MRI and/or CT. 
 
Results: Plasma CgA levels were increased in only 15 of 95 patients (16%). Thirty-three of 
the 95 patients (35%) had increased urinary excretion rates of catecholamines. Six of these 
33 patients (18%) had increased plasma CgA levels. Nine of the 62 patients (15 %) with a 
biochemically silent tumor (i.e. no increased urinary excretion of catecholamines or their 
metabolites) had increased CgA levels. 
Increased plasma CgA levels were positively correlated with urinary excretion rates of 
norepinephrine (r=0.68, p=0.005) and normetanephrine (r=0.68, p=0.005). There was a 
positive correlation between maximal HNPGL diameter and plasma CgA levels in the 57 
patients with a single HNPGL (r=0.57, p=0.001).  
 
Conclusions: Plasma CgA levels are increased in only a small portion of patients with 
hereditary HNPGL and have limited additional value to the combination of radiological and 
routine biochemical assessment of HNPGL patients. Increased plasma CgA levels are 

















Head and neck paragangliomas (HNPGL) are rare neuroendocrine tumors derived from 
parasympathic ganglia (1). Paragangliomas can occur as a consequence of a mutation in 
genes of the succinate dehydrogenase (SDH) family (2-4). These SDH genes (SDHA, 
SDHB, SDHC and SDHD) encode the four subunits of complex II of the mitochondrial 
electron transport chain. SDH contributes to the energy metabolism as a component of the 
tricarboxylic acid cycle, converting succinate to fumarate, and by serving as a source of 
electrons for mitochondrial respiration, as complex II of the electron transport chain (5). 
Except for the SDHA gene, mutations of SDHB, SDHC and SDHD genes are associated 
with familial paraganglioma syndromes (2;6). In the Netherlands, a large proportion of 
hereditary paragangliomas are caused by mutations in the SDHD gene, but mutations in 
SDHB, SDHC and SDHAF2 are also found (5;7-10).  
Although HNPGL have the ability to produce and secrete catecholamines (11;12), we 
recently demonstrated that only 29% of patients with HNPGL have evidence of increased 
urinary excretion of catecholamines and/or their metabolits (13). Consequenly, the majority 
of these patients have biochemical silent tumors and the clinical characteristics of these 
HNPGL can be evaluated only by imaging techniques.  
Chromogranin A (CgA) is a secretory protein from neuroendocrine cells that mediates 
chromaffin granule biogenesis, necessary for catecholamine storage (14;15). CgA is 
secreted from neurosecretory vesicles, along with catecholamines (16). In accordance with 
these biological concepts, plasma CgA is a usefull tumor marker in patients with 
pheochromocytoma (17-23). Lloyd et al. demonstrated the presence of chromogranin in 
head and neck paraganglia, indicating the presence of secretory granules(24). At present the 
clinical relevance of the measurement of plasma CgA levels in patients with hereditary 
HNGPL is unclear. Therefore, the aim of the present study was to assess the prevalence of 
increased CgA levels in patients with hereditary HNPGL and to identify a possible role of 
CgA in patients with biochemically silent tumors. 
 
Patients and Methods 
 
We evaluated in a cross sectional study the clinical, biochemical and radiological data of 95 
consecutive patients with hereditary HNPGL. These patients were selected from all 
HNPGL patients who were followed in the outpatient clinic of the Leiden University 
Medical Center, a tertiary referral center for patients with paragangliomas. Inclusion critera 
for participation in the study were the presence of HNPGL, biochemical screening of 
catecholamine excretion in two 24-h urinary samples, plasma sample for CgA analysis and 
genetic screening for SDH mutations. Exclusion criteria were the use of proton pump 
inhibitors (25), no radiological assessment in case of increased catecholamine excretion, the 
presence of paragangliomas in the thorax or abdomen and because renal failure is 
associated with increased plasma CgA levels, patients with a GFR of less than 60 mL/min 
were also excluded from the study (26). 
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All patients were investigated according to structured protocols, which were standard care. 
These included questions focused on tumor and catecholamine related signs and symptoms, 
measurement of blood-pressure in the supine position, and after 5 minutes of upright 
position, in order to screen for orthostatic hypotension. Repetitive head and neck MRI was 
performed with intervals of at least 2 years. Biochemical screening included the 
measurement of catecholamine excretion in two 24-h urinary samples: (nor)metanephrines, 
(nor)epinephrine, vanillylmandelic acid (VMA), dopamine and 3-methoxytyramine. Urine 
was collected during 24 hours in duplicate under strict dietary regulations (patients 
abstained from pineapple, avocado, bananas, kiwi, nuts, plums, coffee, tea and other 
caffeine containing beverages from 2 days preceding and during urine collection) and after 
withdrawal of medication for at least one week or after changing antihypertensive 
medication to doxazosin. In order to ascertain adequacy of collection, urinary creatinine 
excretion was measured as well. Plasma samples for CgA analysis were stored at -80 ºC 
until analysis.  
In case of excessive catecholamine excretion (i.e., any value above the upper reference 
limit in two urine samples), radiological assessment by MIBG-scans and MRI and/or CT 
scans of thorax and abdomen was performed to identify the source of excessive 
catecholamine production.  
The study was an evaluation of routine patient care. According to the requirements of the 
Dutch law, it was not necessary to obtain permission from the institutional ethical 





Epinephrine, norepinephrine and dopamine excretion rates in 24-h urine collections were 
quantified by reversed high pressure liquid chromatography (HPLC) by an electrochemical 
detector. Inter- and intra-assay coefficients of variations CVs for epinephrine were 4.3-
9.0% ranging from high to low levels. For norepinephrine these data are 2.7-3.6% and for 
dopamine 3.1-4.8%. Vanillylmandelic acid (VMA) excretion in urine was measured using 
HPLC with fluorometric detection with inter- and intra-assay CVs of 2.4-9.1%. (Nor) 
metanephrine and 3MT were determined by stable isotope mass fragmentography. The 
coefficients of variations of the 3-O-methylated catecholamine metabolites (metanephrine, 
normetanephrine and 3MT) ranged from 1.7 to 4.2% (27). Plasma chromogranin A level 
was determined by solid phase two-site immunoradiometric assay (CIS Bio International, 
Gif-sur-Yvette, France).   
Reference ranges were obtained in healthy volunteers. These values were for urinary 
excretion: norepinephrine 0.06-0.47 µmol/24h, epinephrine <0.16 µmol/24h, dopamine 
0.46-3.40 µmol/24h, VMA <30 µmol/24h, metanephrine 33-90 µmol/mol creatinine, 
normetanephrine 64-260 µmol/mol creatinine and 3MT 45-197 µmol/mol creatinine (28), 
plasma chromogranin < 98 ng/mL. SDH mutation analysis was performed by restriction 






SPSS for windows version 16.0 (SPSS inc., Chicago, IL) was used for data analysis. 
Results are expressed as means±standard error (SE), unless specified otherwise. 
Independent sample t-tests and chi-square tests were used to compare patients with and 
without increased plasma levels of CgA. The average value of catecholamine excretion 
rates of two urine samples was used for calculation of p values. Pearson’s correlation test 
was used to study dependence between variables. A p-value <0.05 was considered to 




Clinical and biochemical data of patients with increased versus normal CgA levels 
Plasma CgA levels were increased in 15 of the 95 patients with hereditary HNPGL (16%). 
Tumor related signs and symptoms (e.g., palpitations, diaphoresis, headache, flushes, 
dizziness, tinnitus, hearing loss, hoarseness, nausea, vomiting) were not different between 
patients with increased plasma CgA levels and patients with normal CgA levels (p= 0.26).  
Six of these 15 patients (40%) with increased CgA levels had increased 24 hour urinary 
excretion rates of catecholamines: 2 patients had an elevated urinary excretion rate of 
norepinephrine, 2 patients of dopamine, 4 patients of VMA, 2 patients of normetanephrine, 
3 of metanephrine and 5 patients of 3-methoxytyramine (Table 2). Although none of these 
patients had increased urinary excretion rates of epinephrine, urinary excretion rates of 
epinephrine and VMA were significantly higher in the 15 patients with increased plasma 
CgA levels compared to the patients with normal plasma CgA levels (Table 2). 
Twenty-seven of the 80 patients with normal CgA levels (34%) had increased urinary 
excretion rates of catecholamines: 4 patients had elevated excretion rates of norepinephrine, 
5 of dopamine, 7 of VMA, 1 of metanephrine, 1 of normetanephrine and 19 of 3MT. The 
number of patients with increased urinary catecholamine excretion rates was not 
significantly different between the patients with increased CgA levels versus the patients 
with normal CgA levels (40% vs. 34%, p=0.77). 
 
Biochemical data of patients with increased versus normal rates of urinary catecholamine 
excretion 
Thirty-three of the 95 patients (35%) had increased urinary excretion of catecholamines. 
Six of these 33 patients (18%) had increased plasma CgA levels. Nine of the sixty-two 
patients (15 %) with a biochemically silent tumor (i.e., no increased urinary excretion of 
catecholamines or their metabolites) had increased CgA levels. Of the 9 patients with 
increased CgA levels and a biochemical silent tumor, 7 (78%) had glomus caroticum 
tumors, 5 (56%) glomus vagale tumors, 2 (22%) and 1 (11%) had glomus 
jugulotympanicum tumors. Mean maximal tumor diameter was 4.4±0.8 cm (range 2-9.7 
cm). The number of HNPGL varied from 1 to 4 tumors, the median number of HNPGL was 
2. Eight of these patients had SDHD mutations, and 1 patient a SDHB mutation. 
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Table 1: Clinical characteristics of 95 patients with hereditary HNPGL, with and without 
increased plasma chromogranine A levels. 
 
              Plasma chromogranin A 
             Normal                   Elevated  
 
 
Patient characteristics   p-value 
Age (yrs) m (range) 46 (14-69) 52 (32-78) 0.10 
Gender N (%) 
        Men 








BMI (kg/m2)  25 ± 0.5 23 ± 1 0.27 
Systolic BP (mm Hg) 133 ± 2 136 ± 6 0.54 
Diastolic BP (mmHg) 79 ± 1 83 ± 3 0.17 
Heart rate (beats/min) 72 ± 1 76 ± 3 0.19 
Symptoms/signs 49 (61%) 7 (47%) 0.26 
Type of glomustumor 
       Caroticum 
       Jugulare 
       Vagale 
       Jugulotympanicum 



















Number of HNPGL 
       1 
       2 
       3 

















       SDHD  
       SDHB  














Biochemical and genetic correlations with CgA levels in HNPGL patients 
In the 15 patients with an increased CgA level, CgA levels correlated positively with 
urinary excretion of norepinephrine (r=0.68, p=0.005), normetanephrine (r=0.68, p=0.005) 
and VMA (r=0.67, p=0.006). In the patients with normal plasma CgA levels, there was a 




The prevalence of SDHB and SDHD mutations was not different between patients with 
increased CgA levels and patients with normal CgA levels.  
 
Table 2: Urinary catecholamine excretion rates in 95 HNPGL patients, with and without 
increased plasma chromogranine A levels.  
 
A patient is considered to be positive for the urinary excretion of a specific catecholamine or metabolite if the 
value is above the reference limit in two consecutive urine samples.  
 
Radiological assessment 
Radiological studies of the head and neck region were performed in all 95 patients. 
Radiological evaluation of the head and neck region was performed by MRI in 94% of 
                    Plasma chromogranin A level     
 normal elevated normal elevated  
catecholamines N tested pos N tested pos Mean ± SE Mean ± SE  p-value 
Epinephrine  
(µmol/24 h) 
























19 (24%) 5 (33%) 266 ± 55 761 ± 426 0.27 
Chromogranin A  
(ug/ L) 
80 15 58.5 ± 2.1 167 ± 19 0.00 
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patients, and by CT-scanning in 6% of the patients. We refer to Table 1 for further details 
of the type and number of HNPGL. 
There was no significant difference in the number and type of HNPGL between the patients 
with normal and increased CgA levels. Most patients had carotid body tumors (78%). 
Most patients with HNPGL (n=59) had multiple HNPGL, which prohibited the 
identification of a culprit lesion of CgA secretion. We identified 36 patients with only a 
single HNPGL. In these 36 patients there was a positive correlation between maximal 
tumor diameter and plasma CgA concentrations (r=0.57, p=0.001).  
 
Table 3: Plasma CgA levels and urinary catecholamine excretion rates in 95 HNPGL 
patients with normal and increased urinary catecholamine excretion. 
 
A patient is considered to be positive for the urinary excretion of a specific catecholamine or metabolite if the 





 Urinary catecholamine excretion        
  normal elevated  
catecholamines N tested pos Mean ± SE Mean ± SE  p-value 
Epinephrine  
(µmol/24 h) 
0 0.02 ± 0.0   
Norepinephrine 
(µmol/24 h) 
6 0.36 ± 0.1 1.3 ± 0.5 
 
1.3 ± 0.5 0. 3 
Dopamine 
(µmol/24 h) 
7 1.8 ± 0.1 4.8 ± 0.5 0.001 
VMA 
(µmol/24 h) 
11 21.3 ± 0.7 38.3 ± 2.7 0.000 
Metanephrine 
(µmol/molcre) 
4 51.5 ± 2.1 125 ± 12 0.000 
Normetanephrine 
(µmol/molcre) 
3 146 ± 4.7 828 ± 334 0.18 
3M-tyramine 
(µmol/molcre) 
24 102 ± 5.0 1062 ± 280 0.002 
Plasma CgA levels  
(ug/L)                          
15 58.5 ± 2.1 167 ± 19 0.000 
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Additional radiological analysis 
In the 33 patients with increased urinary excretion of catecholamines and/or their 
metabolites, abdominal/ thoracic paragangliomas were excluded by MRI in 5 patients, by 
MRI and MIBG in 13 patients, by CT and MIBG in 1 patient, by MIBG and abdominal 
MRI in 11 patients, by MIBG alone in 2 patients. In 1 patient abdominal paragangliomas 




The present study was designed to assess the prevalence of increased CgA levels in patients 
with HNPGL and the clinical relevance of CgA measurements in these patients. Plasma 
CgA levels correlated positively with the urinary excretion of norepinephrine, 
normetanephrine and VMA. Moreover, in patients with a single paraganglioma there was a 
positive correlation between maximal paraganglioma diameter and plasma CgA levels. 
Therefore, increased plasma CgA concentrations are associated with increased urinary 
excretion of catecholamines and their metabolites and tumor size in patients with HNPGL. 
However, only 16 % of all HNPGL patients, and only 15 % of the patients with 
biochemically inactive HNPGL had increased plasma CgA concentrations. Therefore, the 
practical implications of CgA measurements are limited in HNPGL patients.  
CgA has been proposed as a tumor marker in patients with pheochromocytomas. The 
sensitivity to detect these tumors ranges from 83-90% (18;19;22;23;30). However, the 
sensitivity in patients with paragangliomas is much lower compared to 
pheochromocytomas, because we observed that only 16% of patients with hereditary 
HNPGL without evidence of pheochromocytomas had increased plasma CgA levels.   
There is a positive correlation between tumor load and plasma CgA concentration (22;31). 
As patients with head and neck paragangliomas have relatively small tumors, the 
concentrations of CgA in our patients are relatively low compared to patients with other 
neuro-endocrine tumors (23). Some of our patients were only identified with HNPGL after 
a family member was found to have a SDHx mutation. Because family members of an 
affected individual are screened for HNPGL, these tumors are found in relatively early 
stages. Therefore, the prevalence of increased CgA levels in patients with HNPGL detected 
by screening is probably very low. This is in line with the findings of Neumann et al., who 
reported a lower sensitivity of CgA for the detection of pheochromocytoma in patients with 
hereditary disease compared to patients with sporadic pheochromocytomas (32). The 
difference in sensitivity can be explained by the fact that these pheochromocytomas were 
found by screening at earlier stage, when the tumor was smaller. 
Nobels et al. observed a positive correlation between tumor load and CgA secretion (23). 
We found no correlation between the number of HNPGL and plasma levels of CgA. This is 
probably caused by the relatively small size of the HNPGL. Because most patients have 
more than one tumor, it is difficult to identify a relationship between the size of the tumor 
and plasma CgA level. We identified 36 patients with only a single HNPGL and in these 
patients plasma CgA level was positively related with the diameter of the HNPGL, in 
accordance with the notion put forward by Nobels et al. 
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Chromogranin A (CgA) mediates chromaffin granule biogenesis, is necessary for 
catecholamine storage and is secreted from neurosecretory vesicles, along with 
catecholamines (14;15). We found a significant correlation between plasma CgA level and 
urinary excretion rates of noradrenaline and normetanephrine, but not with urinary 
dopamine and 3-methoxytyramine excretion. This indicates that increased plasma CgA 
levels are associated with increased noradrenergic activity, but not with increased 
dopaminergic activity. This raises the possibility that there are differences between the 
secretion of norepinephrine versus dopamine by HNPGL in relation to that of CgA. 
However, at present the precise role of CgA in the monoamine sorting process in the 
chromaffin cells is still unclear and additional studies are required to elucidate the role of 
CgA in the sorting and transport of dopamine into granule vesicles.  
The patients with increased plasma CgA levels had higher excretion rates of epinephrine 
and metanephrine compared to the patients with normal plasma CgA levels. Epinephrine is 
released together with CgA after sympatho-adrenal stimulation. The question erases 
whether sympatho-adrenal stimulation might be the cause of the higher mean epinephrine 
and metanephrine excretion in the patients with increased CgA levels. It is known from 
earlier reports that metanephrine levels increase significantly after physical activity, 
changes in posture, caffeine or food intake (33;34). Because our patients collected urine 
under strict dietary regulations, the influence of food and caffeine intake was kept to a 
minimum. We cannot prevent the influence of physical activity and changes in body 
posture during urine collection, but we expect these circumstances to occur similarly in 
both patient groups. Metanephrine levels are also influenced by age and gender (33;35;36). 
Metanephrine levels are significantly higher in men compared to women, furthermore 
metanephrine levels increase with age (33). However, there were no differences in age and 
gender between both groups. Therefore, we cannot simply explain the relation between 
CgA and catecholamine levels by confounding parameters other than HNPGL. 
It has been reported previously that plasma CgA levels are particularly elevated in patients 
with malignant pheochromocytoma (37). Our cohort consisted of only patients with benign 
HNPGL as part of genetic syndromes caused by SDHB or SDHD mutations. We found no 
differences in the prevalence of mutations in the SDHD and SDHB genes between HNPGL 
patients with increased versus normal CgA levels. Additional studies are required to 
evaluate the role of CgA as a tumor marker in patients with malignant HNPGL. 
In patients with pheochromocytoma, postoperative CgA levels are a good index of the 
curative outcome of surgery (18;21). Because patients with HNPGL have much smaller 
tumors and therefore lower plasma CgA levels, it remains questionable whether plasma 
CgA levels are useful as tumor marker in tracking treatment. Therefore, the role of CgA as 
a potential tumor marker for follow-up of patients with HNPGL remains to be elucidated. 
In conclusion, the measurement of CgA in patients with HNPGL has limited additional 
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Pheochromocytomas detected by biochemical screening in predisposed 
subjects are associated with a lower prevalence of clinical and biochemical 
manifestations and smaller tumors than pheochromocytomas detected by 
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Context: Sporadic pheochromocytomas are detected by clinical signs and symptoms, 
whereas pheochromocytomas in patients with a known hereditary predisposition for these 
tumors are detected by repetitive screening for catecholamine excess. 
 
Objective: To document the clinical, biochemical, and pathological differences between 
patients with sporadic pheochromocytomas detected by signs and symptoms and patients 
with pheochromocytomas, detected by biochemical screening in established hereditary 
syndromes  
 
Design: Retrospective follow-up study. 
 
Patients and Methods: We included 60 consecutive patients diagnosed with 
pheochromocytoma (pheochromocytomas detected by signs and symptoms: n=28, 
pheochromocytomas detected by screening: n=32) in our center. 
 
Results: Patients with pheochromocytomas detected by screening presented with less 
complaints of diaphoresis (p<0.01), palpitations (p=0.01), paleness (p=0.01), nausea 
(p<0.01) and vomiting (p=0.01) compared to patients with symptomatic 
pheochromocytomas. Patients with pheochromocytomas detected by screening tended to be 
younger at the time of diagnosis (41±2 vs. 47±3 years, p= 0.07). In addition, patients with 
pheochromocytomas detected by screening had significantly lower rates of 24-hour urinary 
catecholamine excretion, and considerably smaller tumors (3.7 ± 0.5 vs. 7.3 ± 0.7 cm, 
p<0.01).  
 
Conclusions: Pheochromocytomas detected by screening of patients with a hereditary 
predisposition have a much lower prevalence of signs and symptoms, lower catecholamine 
excess and smaller tumors, compared to sporadic pheochromocytomas, detected by signs 
and symptoms. These data support the benefits of screening for pheochromocytomas in 















Pheochromocytomas are rare neuroendocrine tumors derived from chromaffin tissue within 
the adrenal medulla(1). In 12-24% of cases of an apparently sporadic presentation, a 
pheochromocytoma is caused germline mutations in the von Hippel-Lindau gene (VHL), 
the RET gene (leading to MEN2), the neurofibromatosis type I gene (NF1) or one of the 
SDH genes encoding for subunits B, D and C of mitochondrial succinate dehydrogenase (2-
8).  
Sporadic pheochromocytomas are usually identified by signs and symptoms, including 
paroxysms of headache, sweating, palpitations and hypertension resulting from the release 
of catecholamines from the tumor(9). However, a substantial proportion of patients with 
pheochromocytomas do not have signs and/or symptoms, which carries the risk of 
unexpected life-threatening catecholamine crises. Therefore, the advice is to screen patients 
with a known hereditary predisposition for the development of pheochromocytomas at 
regular intervals by measurement of plasma levels and/or urinary catecholamine excretion 
rates(10). In case a pheochromocytoma is detected, adrenalectomy is indicated after 
appropriate pre-operative care (11).  
The benefits of screening may be intuitively reasonable, but these have not been formally 
tested. Therefore, we conducted a retrospective study comparing the data of patients with 
pheochromocytomas detected by signs and symptoms and of patients with 
pheochromocytomas, detected by biochemical screening in hereditary syndromes.  We 
compared signs and symptoms, biochemical parameters, (peri)operative outcome and long-
term results between these groups.  
 
Patients and methods 
 
We included 60 consecutive patients treated at our center between 1975 and 2008 by 
adrenalectomy for pheochromocytomas. The Leiden University Medical Center is a tertiary 
referral center for patients with pheochromocytomas. Of these 60 patients, 28 patients had a 
sporadic pheochromocytoma, detected because of signs and symptoms of catecholamine 
excess, whereas 32 patients had a pheochromocytoma detected by screening in subjects 
with a hereditary predisposition. Hereditary predisposition, which indicated the need for 
biochemical screening, was defined by a positive family history with phenotypic evidence 
of a syndrome, predisposing for pheochromocytomas and/or the presence of germline 
mutations of the RET, VHL, NF1 or SDH genes, respectively. Patients who presented with 
signs and symptoms, which resulted in the diagnosis and treatment of pheochromocytoma 
were defined as having sporadic pheochromocytomas. In patients with hereditary 
pheochromocytomas, clinical follow-up and screening for catecholamine excess was 
performed at least every two years. In case of excessive catecholamine excretion abdominal 
MRI and/ or CT scanning was performed.  
One patient was incidentally diagnosed with a pheochromocytoma after CT scanning 
because of a rectal adenoma. The patient had no catecholamine related signs or symptoms, 
an increased urinary excretion rate of catecholamines and a 5.2 cm tumor in the right 
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adrenal. Because the aim of the study was to compare the clinical features of patients with 
pheochromocytomas who present with tumor and/or catecholamine related signs or 
symptoms versus patients who are screened for pheochromoctyoma we could not classify 
this patient into one of these categories. Therefore the patient was excluded from the study. 
All patients were investigated at the outpatient clinic according to structured clinical 
protocols, which were standard care. These included questions focused at tumor- and 
catecholamine related signs and symptoms, measurement of blood-pressure in the supine 
position, and after 5 minutes of upright position, in order to screen for orthostatic 
hypotension. 
The diagnosis of pheochromocytoma was established by increased urinary excretion rates 
of catecholamines and/or their metabolites, and confirmed by pathological examination. 
Radiological evaluation was performed by a combination of ultrasonography, CT, MRI and 
MIBG scanning. Clinical, endocrinological, radiological, and (peri) operative data were 
available for all patients. 
 
 
Prior to surgery the patients were treated with alpha receptor-blocking drugs (doxazosin or 
phenoxybenzamin) titrated on orthostatic hypotension followed by beta-blockade 
(propanolol) if necessary (pulse rate >70 bpm during alpha-blockade), and intravenous 
hydration with isotonic saline the day preceding the operation. Hemodynamic instability 
during surgery was defined as an episode of systolic arterial pressure above 160 mm Hg 
and/or a mean arterial pressure <60 mmHg. All episodes were counted and the total 
duration of hyper/hypotension was recorded. Complications occurring in the pre-, peri- and 
postoperative periods were recorded. A diagnosis of malignancy was made in case of 
distant metastases and/or local recurrence. Recurrence was defined as the reappearance of 
the disease after eradication of the tumor had been confirmed by negative biochemical and 
imaging tests. The diameter of the tumor was determined on postoperative histopathology. 
The study was an evaluation of routine patient care. According to the requirements of 
Dutch law, it was not necessary to obtain permission from the institutional ethical 
commission. Prior to germ line mutation testing, informed consent was obtained from each 
patient.  
The screening group comprised 32 patients, 17 with familial paraganglioma syndrome (16 
with a SDHD mutation, 1 unknown), 12 with MEN2, 2 with neurofibromatosis and 1 with 
Von Hippel Lindau disease. In the patients with familial paraganglioma syndrome 14 
patients were known with head and neck paragangliomas and were screened for 
pheochromocytoma, 3 patients were referred for screening because a SDH mutation was 
found in a family member. In the MEN2 patient group, 11 patients were known with the 
disease and were screened for pheochromocytoma, 1 patient was screened for 
pheochromocytoma after his son was diagnosed with MEN2 syndrome and was found to 
have a tumor. Both patients with neurofibromatosis were diagnosed with 
pheochromocytoma after they were screened for pheochromocytoma. One patient with a 
heamangioblastoma of the retina was referred to the department of endocrinology because 







Excretion rates of epinephrine, norepinephrine and dopamine in 24 h urine collections were 
quantified by reversed high pressure liquid chromatography (HPLC) by electrochemical 
detector. CVs for epinephrine were 4.3-9.0% ranging from high to low levels. For 
norepinephrine these data were 2.7-3.6% and for dopamine 3.1-4.8%. Vanillylic mandelic 
acid (VMA) in urine was measured using HPLC with fluorometric detection with inter- and 
intra-assay CVs of 2.4-9.1%. Reference ranges were obtained in healthy volunteers. These 
values were for norepinephrine 0.06-0.47 µmol/24h, epinephrine <0.16 µmol/24h, 
dopamine 0.46-3.40 µmol/24h, and VMA <30 µmol/24h (12). In order to ascertain 
adequacy of collection, the urinary creatinine content was assessed as well. Urine samples 





SPSS for windows version 16.0 (SPSS inc., Chicago, IL) was used for data analysis. 
Patients were divided in a sporadic and a hereditary group. Results are expressed as means 
± standard error (SE), unless specified otherwise. Independent sample t-tests and chi-square 
tests were used to compare the data obtained in patients screened for hereditary 
pheochromocytomas and those in patients with sporadic pheochromocytomas. A p-value 




Clinical characteristics (Table 1) 
Patients with pheochromocytomas detected by biochemical screening, presented with 
significantly less complaints of diaphoresis, palpitations, paleness, nausea, vomiting and a 
significantly lower prevalence of type 2 diabetes mellitus, significantly lower systolic blood 
pressure and significantly lower mean arterial pressure compared to patients with 
pheochromocytomas detected by signs and symptoms (Table 1). The classical triad of 
diaphoresis, palpitations and headache was reported by only 5 of 32 patients with 
pheochromocytomas detected by screening (16%) and by 11 of 28 patients (39%) with 
sporadic pheochromocytomas (p=0.04 between both groups). Ten patients in the screening 
group (31%) had no tumor or catecholamine related signs or symptoms. In addition, 
patients with pheochromocytomas detected by screening tended to be younger at the time of 
diagnosis.  
The mean age of the hereditary paraganglioma patients was 46 ± 3 yrs (range 25- 65 yrs), 
36 ± 4 years (range 19- 61 yrs) for the MEN2 patients, 27 ± 11 yrs (16- 38 yrs) for the NF 
patients and 37 yrs for the patient with Von Hippel Lindau disease.  
Time between presentation and surgery was 81 ± 28 days (mean ± SE) in the sporadic 
group. Time between diagnosis of pheochromocytoma and surgery was 420 ± 162 days 
(mean ± SE) in the screening group. Patients in the screening group had been observed for 
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an average duration of 8.4 ± 1.5 years (mean ± SE). In the sporadic group, two patients 
were diagnosed with a hereditary syndrome after surgery. One patient was diagnosed with 
MEN2 disease and one patient was diagnosed with neurofibromatosis. 
 
Table 1: Clinical characteristics at the time of diagnosis of patients with sporadic 
pheochromocytomas versus with pheochromocytomas detected by screening. 
 
Data are shown as mean (SEM), unless mentioned otherwise. 
 
Biochemical results (Table 2) 
All patients had increased 24 hour urinary excretion rates of catecholamines and/or their O-
methylated metabolites ((nor) epinephrine, dopamine, and/or VMA). Patients with 
pheochromocytomas detected by biochemical screening had lower rates of urinary 




         Pheochromocytomas   
Characteristics sporadic screening  p-value 
Number of patients 28 32  
Gender (n (%)) 







Body mass index (kg/m2)  24.5 ± 0.7 25.3 ± 0.7 0.44 
Age at diagnosis (yr) 47 ± 3 41 ± 2 0.07 
Symptoms (n(%))    
         diaphoresis 21 (75%) 11 (34%) <0.01 
          palpitations 18 (64%) 9 (28%) 0.01 
          headache 16 (57%) 12 (38%) 0.13 
          diap. + palp. + head. 11 (39%) 5 (16%) 0.04 
          dizziness 9 (32%) 9 (28%) 0.74 
          pallor 12 (43%) 4 (13%) 0.01 
          nausea 12 (43%) 1 (3%) <0.01 
          vomiting 6 (21%) 0 <0.01 
          flushes 2 (7%) 5 (16%) 0.43 
Hypertension (>140/90 mmHg) 15 (54%) 11 (34%) 0.13 
Type 2 diabetes mellitus (n (%)) 5 (18%) 1 (3%) 0.01 
Systolic blood pressure (mmHg) 156.4 ± 4.7 143.1 ± 2.8 0.02 
Mean arterial pressure (mm Hg) 116.0 ± 3.5 106.8 ± 2.0 0.03 
Diastolic blood pressure (mm Hg) 95.7 ± 3.4 88.6 ± 1.9 0.07 
Antihypertensive medication (n (%)) 13 (46%) 4 (13%) <0.01 
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Table 2: Biochemical characteristics of patients with sporadic pheochromocytomas  
versus pheochromocytomas detected by screening. 
 




In 40 patients with 44 pheochromocytomas additional 
123
MIBG-scanning was performed. 
Overall, 35 of 44 (80%) adrenal tumors showed increased uptake. Patient based sensitivity 
of MIBG scanning was 77% in the screening group and 86% in the sporadic group. MIBG 
uptake was increased in 7/7 of MEN2, 12/16 PGL patients and 1/2 of NF patients. No 
increased uptake was shown in the patient with Von Hippel Lindau disease. Tumors of 
patients with a positive MIBG scan tended to be larger than in the patients with a negative 
scan (3.4±0.6cm vs. 2.5±0.7 cm; p=0.08).  
 
Intra- and post-operative events 
Laparoscopic surgery was performed in 18% of patients in the sporadic group versus 59% 
in the screening group. Open surgery was performed in 82% of patients in the sporadic 
group versus 41% in the screening group. There was no difference in the number of 
complications between the patients treated with laparoscopic surgery versus open surgery 
                Urinary catecholamine excretion     
 sporadic screening sporadic screening  











12.8 ± 1.1 
 
1.9 ± 0.5 
13.8 ± 0.8 
 



















21/ 23 20/ 30 127.2 ± 42.1 ± 4.2 <0.01 
 
Positive urine sample 28/ 28 32/ 32    
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(p= 1.00). There were no differences in duration of surgery, blood loss and hemodynamic 
instability between the two groups. Adverse intraoperative events or complications 
occurred in 9 patients in the patients with pheochromocytomas detected by screening and in 
11 patients in the sporadic group (NS). There were no perioperative deaths or 
cardiovascular events.  
 
Table 3: Peri-operative findings 
           Pheochromocytomas   
Intra-operative events sporadic screening p- value 
Operation time m (min) ± SEM 175 ± 20 167 ± 18 0.78 
SAP> 160 mm Hg 
       Episodes m ± SEM 
       Duration m ± SEM 
21 (75%) 
4.1 ± 0.8 
50.3 ± 10.7 
16 (50%) 
3.7 ± 0.7 




MAP< 60 mm Hg  
       Episodes m ± SEM 
       Duration m ± SEM 
16 (49%) 
2.3 ± 0.7 
20.4 ± 8.6 
11 (34.4%) 
2.6 ± 0.7 













Data are shown as mean (SEM), unless mentioned otherwise. 
Legend: SAP= systolic arterial pressure, MAP= mean arterial pressure. 
 
Pathology 
In the patients with pheochromocytomas detected by screening, 8 patients (25%) had a 
pheochromocytoma in the right adrenal gland, 18 (56%) in the left adrenal gland and 6 
(19%) had bilateral pheochromocytomas. In the sporadic group, 16 of 28 patients had a 
pheochromocytoma located in the right adrenal gland (57%), and 10 patients in the left 
adrenal gland (36%), whereas there was a bilateral pheochromocytoma in 2 patients (7%). 
Pheochromocytomas in the sporadic group were significantly larger compared to the 
hereditary group (7.3 ± 0.7 vs. 3.7 ± 0.5 cm, p< 0.01). One patient in the sporadic group 
had a malignant tumor, reflected by metastatic disease.  
  
Longterm follow-up 
Mean follow-up time was 7.5 ± 1.4 years in the patients with pheochromocytomas detected 
by screening and 7.8 ± 1.4 years in the patients with sporadic pheochromocytomas. In the 
patients with pheochromocytomas detected by screening, 6 patients (5 with MEN 2A and 1 
with hereditary paragangliomas) developed a pheochromocytoma in the opposite adrenal 
gland, but none developed metastatic or locally recurrent disease. In the patients with 
sporadic pheochromocytomas, 1 patient developed a second pheochromocytoma, 1 patient 
metastatic disease and 1 patient local recurrence and metastases. In the sporadic group, 2 
Chapter 6 
92 
patients died of non tumor-related conditions, whereas the cause of death in 1 other patient 




We compared the differences between patients with pheochromocytomas detected by 
biochemical screening in hereditary syndromes predisposing for pheochromocytomas and 
patients with sporadic pheochromocytomas (patients with incidentalomas were excluded). 
Our study clearly shows that patients screened for pheochromocytoma because of a 
hereditary predisposition presented with less signs and symptoms, lower urinary excretion 
rates of catecholamines, and smaller tumors than patients presenting with symptomatic 
pheochromocytomas.  
The patients with pheochromocytomas detected by screening had significantly less 
pheochromocytoma-related complaints. This can be explained by the fact that these 
pheochromocytomas are found at earlier stage when the tumor is smaller and produces less 
catecholamines. Our data are in line with those of Pomares et al., who compared patients 
with sporadic pheochromocytomas and patients with pheochromocytomas caused by the 
MEN 2A syndrome. They reported similar differences in age at presentation, clinical signs 
and symptoms, radiological findings, and uni- versus bilateral pheochromocytomas (13). 
We included patients with pheochromocytomas detected by screening for several hereditary 
syndromes predisposing to pheochromocytomas (MEN 2A syndrome, NF1, VHL disease, 
familial paraganglioma syndrome) and patients presenting with sporadic 
pheochromocytomas. In the patients with pheochromocytomas detected by screening, the 
age at presentation was 6 years younger than in the sporadic group, which might reflect a 
benefit of screening and/or earlier development of pheochromocytoma in patients with 
hereditary disease. The ages of the patients with SDHD related pheochromocytoma found 
in our study is higher compared with the mean ages reported in the literature. This 
difference can be explained by the fact that the other studies included children in their 
studies (2, 4, 14). The mean ages of the patients with MEN2, VHL and NF included in our 
study are comparable to those reported in the literature (4, 6, 13, 15, 16).The higher age 
range of our hereditary paraganglioma patients increases the mean age of the hereditary 
patient group in total.  
All our patients had an increased urinary catecholamine excretion. In the patients with 
pheochromocytomas detected by screening, the mean excretion rates of (nor) epinephrine 
were significantly lower compared to patients with sporadic pheochromocytomas. In 
accordance with the study of Eisenhofer et al., who documented a positive relation between 
the size of the pheochromocytoma and urinary catecholamine excretion, the patients with 
the sporadic pheochromocytomas had larger pheochromocytomas and higher urinary 
excretion rates of catecholamines (15).  
The reported sensitivity and specificity of MIBG scanning in patients with (suspected) 
pheochromocytoma ranges from 80- 100%(17-22). MIBG uptake correlates with the 
production of catecholamines(18). The detection rate of MIBG scanning in the screening 
group was lower because of the smaller tumors and the lower biochemical activity.  
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Despite these differences in biochemical activity and the sizes of the pheochromocytomas 
there were no differences between both groups in perioperative complications. There were 
no peri-operative deaths, or cardiovascular events. This was probably related to careful pre- 
and (peri) operative care with careful titration of alpha- and beta blocking drugs.  Patients 
in the screening group were treated more often with laparoscopic surgery. The differences 
in operation method resulted from differences in tumor diameter (larger in the sporadic 
group) and because of the innovation with regard to operation technique during the 
decades. Despite the differences in operation technique, the number of complication was 
not different between the patients treated with laparoscopic surgery versus open surgery. 
Long term follow up revealed additional manifestations of disease in both groups of 
patients. In the patients with a documented hereditary predisposition several patients 
developed an additional pheochromocytoma in the contralateral adrenal gland, especially in 
the case of MEN 2A syndrome (5). In the sporadic group there were several patients with 
malignant pheochromocytomas. Therefore, long term follow up seems to be warranted in 
all pheochromocytoma patients, irrespective of initial presentation.  
The sporadic group also contained patients with germline mutations predisposing to the 
development of pheochromocytomas, which were detected by signs and symptoms because 
they had not been identified previously by prior knowledge of the predisposing hereditary 
syndrome. However, this does not invalidate our conclusions, because we report the 
benefits of screening, once this genetic predisposition has been documented.  
Because the aim of the study was to compare the clinical features of patients with 
pheochromocytoma who present with tumor and/or catecholamine related signs or 
symptoms versus patients who are screened for pheochromoctyoma, we excluded patients 
who presented with an incidentaloma. Studies comparing the clinical features of patients 
with incidentalomas versus patients who presented with adrenergic symptoms reported less 
catecholamine related signs and symptoms, lower plasma catecholamines concentrations, 
similar tumor size and an older age at presentation in the patient group with incidentalomas 
(23-25). Because patients with incidentalomas were excluded from the sporadic group in 
our study, the reported signs and symptoms, the mean urinary catecholamine excretion rate 
and the mean age at presentation found in our study might be different compared to studies 
who included patients with incidentalomas. 
Patients at risk for developing a pheochromocytoma should be regularly screened. The 
diagnostic test of choice is the measurement of fractionated plasma and/ or urinary 
metanephrines (26). Patients with a SDHx mutation, MEN2 disease or Von Hippel- Lindau 
disease are advised to be screened for pheochromocytoma annually. In case of increased 
plasma/ urinary catecholamines or their metabolites, additional radiological investigation 
should be performed to identify the culprit lesion (2, 6, 13, 27). The prevalence of 
pheochromocytoma is quite low in patients with Neurofibromatosis and therefore screening 
is not recommended in all patients, but it may be justified in those patients with 
neurofibromatosis with hypertension, or in those patients who will undergo provocative 
interventions, such as surgery or pregnancy (7). Children who are predisposed to the 
development of a pheochromocytoma should be screened annually. The age of initial 
screening is determined by the specific gene mutation (28). 
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In conclusion, screening for pheochromocytomas in patients with a hereditary 
predisposition for these tumors is associated with a much lower prevalence of signs and 
symptoms, lower values of catecholamine excess and smaller tumors, compared to sporadic 
pheochromocytomas, detected by signs and symptoms. This observational study supports 
the usefulness of a screening program for pheochromocytomas in subjects with hereditary 
predispositions. In addition, we recommend lifelong follow-up in all patients with 
pheochromocytomas, irrespective of the initial manifestation, because of the risk of 
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Objective: To assess whether patients with bilateral carotid body resection (bCBR) or with 
a bilateral carotid body tumor (bCBT) are prone to develop sleep disordered breathing. 
 
Patients and Methods: 9 bCBR patients and 9 bCBT patients were screened for sleep 
disordered breathing by polysomnography. For every patient a healthy age, sex and BMI 
matched control person was screened. In addition chemoresponsiveness to CO2 was tested 
by a rebreathing method. Sleep quality and quality of life were assessed using 
questionnaires. Daytime and nighttime activity levels were measured using actigraphy.  
 
Results: 6 bCBT patients (67%) suffered from severe sleep apnea syndrome. Sleep apneas 
were both obstructive and central in nature. bCBT patients had a significantly higher apneu-
hypopneu index (AHI) compared to their healthy controls (46.4 ± 12.6 events/ hour sleep 
vs. 9.7 ± 1.8 events/ hour sleep, p=0.02).We found no differences in the occurrence of mild, 
moderate and severe sleep disordered breathing between patients with bilateral carotid body 
resection and their healthy controls. The AHI was positively correlated with an increased 
peripheral chemoresponsiveness. bCBT patients had a reduced quality of life and a reduced 
daytime activity level compared to their healthy controls.  
 
Conclusions: Patients with bilateral carotid body tumors are at risk for developing sleep 
disordered breathing. The development of sleep disordered breathing results from an 
increase in peripheral chemoreceptor output, causing ventilatory instability. Sleep 





















Paragangliomas are neuro-endocrine tumors, derived from paraganglia (1)  Germline 
mutations in succinate dehydrogenase (SDH) genes cause familial paraganglioma 
syndromes. Subjects with these SDH mutations have a high prevalence of paragangliomas 
in the head and neck region. Most frequently, paragangliomas develop in the carotid bodies, 
which can be surgically removed (2,3) 
These carotid bodies have important peripheral chemoreceptor functions for sensing arterial 
oxygen concentrations and, to a lesser extent, arterial carbon dioxide concentrations 
4
. 
Accordingly, bilateral resection of carotid body paragangliomas dimineshes the ventilatory 
responsiveness to hypoxia (5). Moreover, after bilateral resection of carotid body 
paragangliomas, ventilatory sensitivity decreases, resulting in increased resting end-tidal 
CO2 pressure (Pet CO2) values (5). In turn, these high resting PetCO2 values are associated 
with irregular breathing, periodic breathing and central sleep apnea (6). Therefore, the 
question arises whether these patients are prone to develop sleep disordered breathing after 
bilateral resection of carotid body paragangliomas.  
At present, it is unknown whether carotid body paragangliomas in situ cause dysfunction of 
peripheral chemoreceptor function and if patients with bilateral carotid body 
paragangliomas have altered chemoreceptor responses. Therefore, the aim of the present 
study was 1) to assess the prevalence of sleep disordered breathing and 2) to test peripheral 
chemoreceptor responsiveness in patients with bilateral carotid body paragangliomas and 
patients after bilateral resection of carotid body paragangliomas.  
 
Patients and methods 
 
Subjects  
We included 9 patients with bilateral carotid body paragangliomas (bCBT) and 9 patients 
who had previously been treated by bilateral resection of carotid body paragangliomas 
(bCBR). These patients were recruited from the outpatient clinics of the departments of 
Endocrinology, Otorhinolaryngology and Surgery of the Leiden University Medical Center 
and through an advertisement on the website of the Dutch paraganglioma patient network. 
All patients who were willing to participate were invited at our outpatient clinic and 
screened for suitability for participation in the study. For each patient we recruited a healthy 
age-, sex- and BMI matched control subject.  
Exclusion criteria were sleeping disorders diagnosed by previous polysomnography, 
psychiatric disorders and/or the use of sleep-influencing medication. 
The Medical Ethics Committee of the Leiden University Medical Center approved the 
study protocol. Written informed consent was obtained from all subjects prior to the study. 
 
Study design 
Prior to the study subjects were asked to collect urine during 24 hour in duplicate under 
strict dietary regulations (patients abstained from coffee, bananas, nuts and alcohol from 
two days before and during the collection of the urine). 
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After an overnight polysomnography subjects were admitted to our clinical research center. 
On the first study day, indirect calorimetry, spirometry and peripheral chemoreflex function 
tests were performed. In addition, self-reported sleep duration, sleep quality and quality of 
life were assessed using validated questionnaires (Epworth Sleepiness Scale, St. George 
Respiratory Questionnaire, Standard Clinical Assessment Questionnaire, The Berlin 
questionnaire, Pittsburgh sleep quality index, Short form 36, Nottingham Health Profile, 
Hospital Anxiety and Depression Scale, and the Multidimensional Fatigue Index) 
7-15
. 
Actigraphy (Actiwatch AW7; Cambridge Neurotechnology, Cambridge, UK) was 
performed to objectively measure habitual sleep duration during 7 days after the study, 
including one weekend (16).  
 
Polysomnography 
Sleep was recorded by a portable polysomnography recorder (Titanium; Embla Systems, 
Inc., Broomfield, CO). Sleep was visually scored according to the guidelines of the 
American Association of Sleep Medicine (17) (Iber C 2007 The AASM manual for the 
scoring of sleep and associated events: rules, terminology and technical specifications. In 
Ancoli-Israel S., Chesson AL, Quan SF, eds. Westchester. IL: American Academy of Sleep 
Medicine). The duration of wake, stage I, II, III and REM sleep was assessed. Total sleep 
duration was the sum of durations of stages I, II, III and REM. Apneas were defined as a 
cessation of airflow at the nose for longer than 10 seconds. Oxygen saturation was 
monitored continuously with a pulse oximeter attached to the index finger.  
 
Indirect calorimetry 
Basal energy expenditure was measured by indirect calorimetry and a canopy system 
(Oxygen Pro; CareFusion, Erich Jaeger, Germany). After an overnight fast from 22.00 hrs, 
measurements started at 10.00 hrs in a quit room at constant room temperature. Subjects 
were asked to relax and close their eyes without falling asleep while lying supine on a bed 
with their head in a canopy. The canopy blower was adjusted to maintain the fraction of 
expired CO2 below 0.800%. The measurement was performed during 45 minutes. The final 
20 minutes were used to calculate Resting Energy Expenditure (REE). .  
 
Spirometry 
To assess lung function, inspiratory vital capacity (IVC) and forced expiratory volume in 1 
second (FEV1) were determined by spirometry. The FEV1/ IVC ratio was calculated. All 
lung function parameters were recorded as a percentage of the value predicted for age, sex 
and length matched controls.  
 
Peripheral chemoreceptor function 
To investigate peripheral chemoreflex function, the ventilatory response to hypercapnia was 
assessed during both normoxic (nVHR) and hyperoxic (hVHR) conditions. We first 
assumed that the peripheral chemoreflex drive is silenced during hyperoxia. Second, during 
the normoxic test we assumed that the central and peripheral drives were additive. Since the 
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additive effect of the peripheral chemoreflex during normoxia is considered 10-20%, the 
peripheral chemoreflex function will be underestimated in our test (18). Subjects were 
connected to a closed spirometric circuit while in the sitting position. Partial pressure of 
carbon dioxide (PCO2) was monitored continuously at the mouth. End-tidal carbon dioxide 
(PetCO2) was controlled by adjusting a three way valve, partially short-circuiting the 
carbon dioxide absorber in the inspiratory limb of the circuit. The nVHR was measured 
during six minutes. After the subject breathed room air for 10 minutes, the test was repeated 
under hyperoxic conditions to measure hVHR. To avoid the stimulation of ventilation by 
100% oxygen, a PetO2 of approximately 150 mmHg (19). The ventilatory respons to 
hypercapnia was assessed by a rebreathing method introduced by Read (20). Differences 
from the classical Read method included use of 4% CO2 concentration and the absence of 
hyperventilation prior to rebreathing. As a result, a difference occurs between central PCO2 
and PetCO2. However, this will diminish slowly over time producing a linear portion of a 
response line in the second half of the test (21). 
The ventilatory respons to hypercapnia was assessed by a rebreathing method (20). 
Ventilation was plotted against PetCO2. Responsiveness was reported as the slope of the 




Adrenaline, noradrenaline and dopamine excretion in 24 hour urine collections were 
quantified by reversed high pressure liquid chromatography (HPLC) by an electrochemical 
detector. CVs for epinephrine were 4.3-9.0% ranging from high to low levels. For 
norepinephrine these data are 2.7-3.6% and for dopamine 3.1-4.8%. Vanillylic mandelic 
acid (VMA) excretion in urine was measured using HPLC with fluorometric detection with 
inter- and intra-assay CVs of 2.4-9.1%. (Nor)metanephrine and 3-methoxytyramine were 
determined by stable isotope mass spectrometry. The coefficients of variation of the 3-O-
methylated catecholamine metabolites (metanephrine, normetanephrine and 3-
methoxytyramine) ranged from 1.7 to 4.2% (22). 
Reference ranges were obtained in healthy volunteers. These values were norepinephrine: 
0.06-3.40 µmol/24h, epinephrine <0.16 µmol/24h, dopamine 0.46-3.40 µmol/24h, VMA 
<30 µmol/24h, metanephrine 33-90 µmol/mol creatinine, normetanephrine 64-260 
µmol/mol creatinine and 3-methoxytyramine 45-197 µmol/mol creatinine (23). SDH 





SPSS for windows version 16.0 (SPSS inc., Chicago, IL) was used for data analysis. 
Results are expressed as means ± standard error (SE), unless specified otherwise. 
Independent sample t-tests and chi-square tests were used to compare patients with their 
healthy controls. We used the dependant t-test for paired samples to compare the difference 
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between nVRH and hVHR within the patient and healthy control groups. A p-value <0.05 
was considered to represent a significant difference. 
 
Table 2: Clinical characteristics of patients with bilateral carotid body tumors and their 
matched healthy controls 
Characteristics  bCBT 
   N=9 
 Controls 
   N=9 
p-value 
Age (yr) 
   Males  
   Females  
55.6 ± 3.3 
56.2 ± 3.5 
54.3 ± 8.0 
53.8 ± 2.7 
55.0 ± 2.5 





   Male  










   Males 
   Females  
27.4 ± 1.2 
27.3 ± 1.1 
27.6 ± 3.4 
26.7 ± 1.3 
26.3 ± 1.0 





  Tumor right (cm) 
Tumor left (cm)  
 
3.1 ± 1.1 (1.0-9.3) 






   Daily activity 
   Nighttime activity 
 
228 ± 14 
23 ± 3 
 
280 ± 24 




Spirometry m (range) 
   FEV1           (% Pred) 
   FEV1/ IVC (% Pred) 
   FEV1/ FVC (%Pred) 
 
102 ± 6 (79-132) 
96 ± 5 (78-116)* 
82 ± 4 (65-93) 
 
108 ± 8 (71-144) 
116 ± 4 (93-125) 






Data are shown as mean values ± SEM, unless specified otherwise. 





We studied 9 bCBT patients and 9 bCBR patients (Table 1 and 2). Mean duration between 
the date of the resection of second carotid body paraganglioma and the current study was 
8.9 ± 2.3 yrs. In the bCBT group one patient had increased 24 hour urinary excretion of 3-
methoxytyramine and one patient increased excretion of both 3-methoxytyramine and 
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norepinephrine. In these patients abdominal/ thoracic paragangliomas were excluded by 
MRI in both patients. In the bCBR group one patient had increased 24 hour urinary 
excretion of 3-methoxytyramine. Seven patients in the bCBT group had SDHD mutations, 
whereas 2 patients were not tested for germline mutations in SDHx genes. In the bCBR 
group 6 patients had SDHD mutations, whereas 3 patients were not tested. In the bCBT 
group 6 patients had additional head and neck paragangliomas (HNPGL). Five patients had 
glomus vagale tumors, one patient a glomus jugulare tumor and one patient a glomus 
tympanicum tumor. In the bCBR, 3 patients had additional HNPGL. Two patients had 
glomus vagale tumors and one patient had a glomus jugulare tumor.  
There were no differences in RER, REE, VCO2 and VO2 between the bCBT patients and 
their controls and between the bCBR patients and their controls. There was no correlation 




Patients with bCBT had reduced quality of life scores compared to their healthy controls. 
They had worse physical (p<0.01) and social functioning (p<0.05) and reduced general 
health perception (p<0.01). They reported more complaints of fatigue (p<0.01), reduction 
in activity (p<0.001), motivation (p=0.001) and worse daytime dysfunction (p=0.01) and an 
increased daytime hyper somnolence (p=0.05). bCBR patients reported impaired physical 
function (p<0.05), complaints of general fatigue (p<0.05), reduced physical fitness (p<0.05) 
and reported more sleep disturbances (p<0.05) compared to the healthy controls. 
 
Sleep apnea 
In the patient group with bilateral carotid body tumors (bCBT), 1 patient suffered from mild 
and 6 patients (67%) suffered from severe sleep disordered breathing. Of these 6 patients, 2 
had obstructive sleep apnea (OSA), 2 had central sleep apnea (CSA), 1 had both OSA and 
CSA and 1 patient had a hypopneu index of 42 events/ hour. In the control group 5 (56%) 
had mild SDB and one moderate SDB. Patients with bCBT had a higher AHI compared to 
healthy controls (46.4±12.6 nr/hrs vs. 9.7±1.8 nr/hrs, p=0.02) and a higher apnea-index (AI) 
compared to controls, although this was not significantly different (22.3±9.2 nr/hrs vs. 2.0 ± 
1.0 nr/hrs, p=0.06). In the patient group with bilateral carotid body resection (bCBR), 3 
patients had mild and 1 patient had moderate SDB. There were no differences in AHI, AI 
and the occurrence of mild, moderate and severe SDB between patients with bCBR and 
their healthy controls. 
Sleep stages 
Patients with bCBT had reduced sleep efficiency (p=0.05) and spent more time in stage 1 
sleep compared to the healthy controls (p=0.02). Patients had a significantly higher AHI 
during non-REM sleep compared to healthy controls (50.2±14.7 vs. 6.1±1.8, p=0.02).  
In the bCBR group, patients spent more time in sleep stage 1 compared to the healthy 
controls.  
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Table 3: The results of polysomnography of 9 bCBT and 9 bCBR patients and their 
matched healthy controls. 
Polysomnography     
    bCBR     Controls bCBT controls 
Total sleep time (min) 416.5 ± 17.4 442.0 ± 10.0 408.3 ± 17.4 462.4 ± 19.3 
Sleep latency (min) 7.7 ± 1.5 4.3 ± 0.6 12.0 ± 5.0 4.7 ± 0.9 
Sleep efficiency (%) 89.9 ± 1.2 91.0 ± 1.1 85.8 ± 2.2* 90.8 ± 0.8 
% Sleep phase 1  12.7 ± 2.0* 7.6 ± 0.7 12.8 ± 1.9* 7.7 ± 0.7 
% Sleep phase 2 38.2 ± 2.9 38.4 ± 2.2 44.1 ± 2.4 40.6 ± 2.2 
% Sleep phase 3 24.8 ± 2.1 27.4 ± 2.2 18.7 ± 3.0 25.5 ± 2.3 
% REM sleep 24.3 ± 2.5 26.7 ± 1.2 24.5 ± 2.0 26.2 ± 1.1 
% awake 8.9 ± 1.3 8.3 ± 1.1 56.7 ± 10.8 39.3 ± 4.8 
Awakenings (nr) 23.7 ± 3.7 22.6 ± 3.9 25.0 ± 2.9 22.3 ± 4.0 
AH index ¹ (nr/h) 
Apneu Index (nr/h) 
   Mild n (%) 
   Moderate n (%) 
   Severe n (%)    
6.5 ± 2.3 




7.7 ± 1.9 




46.4 ± 12.6* 




9.7 ± 1.8 




AH REM index (nr/h) 11.6 ± 3.9 13.3 ± 5.1 31.3 ± 7.7 18.0 ± 5.6 
AH nREM index (nr/h) 4.6 ± 2.5 4.6 ± 1.8 50.2 ± 14.7* 6.1 ± 1.8 
AH mean duration (min) 11.0 ± 5.5 10.6 ± 5.5 21.4 ± 2.7 21.7 ± 1.8 
Obstructive apneu index 
(nr/h) 
0.8 ± 0.4 0.6 ± 0.5 10.1 ± 4.5 0.9 ± 0.5 
Central apneu index (nr/h) 0.4 ± 0.2 1.1 ± 0.8 12.2 ± 6.0 1.1 ± 0.8 
Mixed apneu index (nr/h) 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 
Hypopneu index (nr/h) 7.2 ± 3.0 6.0 ± 1.4 23.2 ± 5.3 14.6 ± 7.6 
 
Data are shown as mean values ± SEM, unless specified otherwise. 
* p-value< 0.05; ** p-value< 0.01; ¹ AH index: Apneu Hypopneu index. 
 
Peripheral chemosensitivity 
In the bCBT group, during normoxic conditions, the 1 kPa increase in PetCO2 induced an 
increase in ventilation of 14.8 ± 2.3 l/min in patients and 13.7 ± 3.1 l/ min in healthy 
controls (NS) (Figure 1). During hyperoxic conditions, the 1kPa increase in PetCO2 
induced an increase in ventilation of 11.0 ± 1.2 l/ min in patients and 9.2 ± 2.9 l/min in 
healthy controls (NS). 
Chapter 7 
106 
The nVRH and hVHR were significantly different in bCBT patients (14.8 ± 2.3 vs. 11.0 ± 
1.2 l/ min, p<0.05).  
In the bCBR group, during normoxic conditions, the 1 kPa increase in PetCO2 induced an 
increase in ventilation of 11.1 ± 2.3 l/ min in patients and 17.7 ± 2.5 l/ min in healthy 
controls (NS). During hyperoxic conditions, the 1kPa increase in PetCO2 induced an 
increase in ventilation of 10.6± 3.0 l/ min in bCBR patients and 15.4 ± 3.0 l/ min in healthy 
controls (NS) (Figure 1).  
 
Figure 1: Ventilatory resonses (VR) to CO2 under normoxic (nVHR) and hyperoxic 
(hVHR)conditions.
 
Correlation between Sleep apnea, BMI and ventilatory responses 
There was no correlation between BMI and AHI, obstructive apnea index, central apnea 
index or hypopnea index in both patient groups and control groups. In the patient group 
with bilateral carotid body tumors, there was no correlation between the occurrence of 
severe SDB and BMI. 
In bCBT patients, there was a highly positive correlation between the apnea-hypopnea 




The aim of the present study was to assess the prevalence of sleep related complaints by 
polysomnography in patients with bilateral carotid body paragangliomas and in patients 
with bilateral resection of carotid body paragangliomas. There was a high prevalence of 
sleep disordered breathing in patients with bilateral carotid body paragangliomas, but not in 
patients after bilateral resection of carotid body paragangliomas. Sleep disordered breathing 
was associated with increased peripheral chemoresponsiveness. Moreover, these subjects 
have an impaired quality of life and a reduced daytime activity level. 
In the past, bilateral resection of carotid bodies was performed in patients with bronchial 
asthma or COPD to alleviate symptoms. Hypoventilation and apneic spells have been 
reported as a consequence of this procedure (26,27). The breathing response to hypoxia 
appeared to be permanently absent after bilateral resection of carotid body paragangliomas, 
which puts patients at risk of developing sleep disordered breathing (SDB) (5,28). 
Carotid body tumors and sleep disordered breathing 
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To assess this risk we performed polysomnography in 9 patients with bilateral resection of 
carotid body paragangliomas. However, we found no increased prevalence of SDB in the 
patients with bilateral resection of carotid body paragangliomas compared to their healthy 
control group, but we did find a high prevalence of SDB in patients with bilateral carotid 
body paragangliomas. In addition, we found a highly positive correlation between the 
apneu-hypopneu index and the difference in VHR under normoxic and hyperoxic 
conditions. This may indicate that the development of SDB is primarily caused by an 
increase in peripheral chemoreceptor output in patients with bilateral carotid body 
paragangliomas. The possible role of upper airway obstruction by paragangliomas of the 
carotid body in association with sleep apnea has been described in a few patients (29,30). In 
our series the relation between the occurrence of airway narrowing on the MRI scan and the 
presence of obstructive apneas was equivocal. Two out of the four patients with an OAI of 
greater than 5 had signs of airway narrowing on static MRI scanning. Further investigations 
such as dynamic MRI scanning and sleep endoscopy will contribute to the role of airway 
narrowing in the group of paraganglioma patients. 
The ventilatory control system is aimed at supplying oxygen to the body with minimum 
changes in pH and CO2. Disturbances in this system result in changes in blood gas tensions 
in the gas stores of the body and in arterial blood. The peripheral and central 
chemoreceptors respond to these changes by sending impulses to regulatory centers in the 
central nervous system, that in turn stimulate the ventilatory muscles to produce a 
ventilatory effort which counteracts the effect of the disturbances on blood gas tensions 
(31,32). During wakefulness non-specific environmental stimuli contribute to the tonic 
activity of muscles that keep the upper airway open. During sleep, the effects of 
environmental stimulations are reduced, which decreases the activity of the chest wall and 
the upper airway muscles and affects the resistance and patency of the upper airway. 
During sleep, chemoreceptors become more important in the regulation of ventilation. The 
tonic and the phasic respiratory activity of the upper airway muscles increase as chemical 
drive intensifies. Studies in humans and animals indicate that upper airway muscles 
frequently have different response characteristics to chemical stimulation than the chest 
wall muscles 
33;34
. There may be a range of stimuli over which the response of the upper 
airway muscles is less than that of the chest wall. In this range airway obstruction can 
occur. Obstructive apnea increases the instability of the respiratory system and an unstable 
system increases the risk of obstructive apneas (35). 
Arterial PaCO2 is regulated by negative-feedback control. Fluctuations in PaCO2 stimulate 
the chemoreflexes to produce ventilatory adjustments to restore PaCO2 back to its original 
target level. As a result of delays in the feedback and control processes oscillation of the 
ventilatory control system may arise. The duration and the magnitude of these oscillations 
are determined by the strength of the chemoreflex response (controller gain) and by the 
amplification with which the ventilatory changes are translated into changes in PaCO2 
(plant gain) (36). The product of controller and plant gain (loop gain) determines the 
stability of the ventilatory system. The higher the loop gain, the less stable the system and 
the higher the probability of periodic breathing. Enhanced peripheral chemosensitivity 
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would increase loop gain and make a subject more prone to develop periodic breathing. 
Indeed, patients with periodic breathing and idiopathic central sleep apnea have increased 
central and peripheral chemosensitivity compared to normal controls (37,38). Furthermore, 
patients with severe obstructive sleep apnea have a more unstable chemical control system 
compared to patients with mild OSA, which might contribute tot the severity of sleep 
disordered breathing (39). We found no difference in peripheral chemorespons to CO2 
between patients and controls under normoxic and hyperoxic conditions. However, the 
patients with bilateral carotid body paragangliomas in situ showed a significantly increased 
ventilatory response to CO2 under normoxic conditions compared to hyperoxic conditions, 
indicating an increased peripheral ventilatory drive. Taken into account that the normoxic 
test is composed of approximately 10-20% of the peripheral chemoreflex drive, this 
difference may be more prominent during hypoxic conditions. More importantly, we found 
a high correlation between the ventilatory response and the apnea-hypopnea index, 
indicating that an increment in ventilatory response on CO2 makes a subject more prone to 
develop SDB.  
The question arises whether the increased chemoresponsiveness in the bCBT patients is 
associated with mutations in the succinate dehydrogenase gene (SDH). Piruat et al. have 
tested whether mice with a partial SDHD deficit have altered carotid body function. They 
found that the loss of an SDHD allele results in an abnormal enhancement of resting CB 
activity. This CB overactivity was linked to glomus cell hypertrophy and hyperplasia (40). 
Therefore, the increased peripheral chemoresponsiveness in the bCBT patients might be the 
result of hyperplasia of carotid body cells, indicating that tumor formation in the carotid 
bodies leads to gain of function rather than loss of function.  
Intermittent hypoxia can lead to the development of systemic hypertension, heart failure, 
myocardial infarction and stroke (41). Therefore, it is important to treat sleep disordered 
breathing. Because of the potential risk of developing sleep disordered breathing, surgery 
must be considered as an alternative to the general wait-and-scan policy. 
Based on these findings all patients with bilateral carotid body tumors should be screened 
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In recent years the multidisciplinairy approach of the Leiden University Medical Center 
(LUMC) towards patients with head and neck paragangliomas (HNPGL) has been 
extended. All patients with HNPGL who consulted the departments of 
Otorhinolaryngology, Endocrinology and/ or Clinical Genetics were screened for 
catecholamine excess according to a routine, structured protocol. The aim of inclusion of all 
consecutive HNPGL patients in the LUMC was to further specify the clinical and 
biochemical characteristics of these patients. Initial screening consisted of measurement of 
24-hour urinary excretion of catecholamines and their O-methylated degradation products 
in duplicate, which was repeated with intervals of 2 years, if initial biochemical screening 
was negative. In patients with excessive catecholamine excretion, imaging studies with 
123
I-
MIBG scintigraphy and whole body MRI and/or CT were performed to exclude additional 
intra- or extra-adrenal non HNPGL.  
In this thesis we describe the genetic, biochemical and clinical characteristics of these 
HNPGL patients. In addition to screening of urinary catecholamine excretion rates, we 
measured plasma metanephrine levels and compared test sensitivity of these plasma levels 
with urinary excretion rates of catecholamines. Furthermore, we assessed whether plasma 
chromogranin A levels has a role as tumor marker in HNPGL patients. A previous study, 
conducted by B. Havekes et al (unpublished data), described an association between 
glomus caroticum tumors and subjective sleep related complaints. To study these 
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complaints in more detail we screened patients with bilateral carotid body paragangliomas 
for sleep disordered breathing. 
II. High prevalence of founder mutations of the succinate dehydrogenase genes 
in the Netherlands 
The hereditary paraganglioma syndrome is caused by mutations in the succinate 
dehydrogenase (SDH) gene. The SDH gene family (SDHA, SDHB, SDHC and SDHD) 
encodes the four subunits of complex II of the mitochondrial electron transport chain. SDH 
contributes to energy metabolism as a component of the tricarboxylic acid cycle, converting 
succinate to fumarate, and by serving as a source of electrons for mitochondrial respiration, 
as complex II of the electron transport chain. Because ~30% of patients with apparently 
sporadic HNPGL are affected by a SDHx mutation, molecular genetic screening should be 
performed in all patients with HNPGL. The LUMC is a dedicated referral laboratory for 
paragangliomas in the Netherlands. As almost all DNA samples of Dutch paraganglioma 
patients are tested in the LUMC, mutation frequency analysis of these patients represents 
the actual prevalence of SDH gene mutations in the Netherlands. Analysis of 1045 
paraganglioma and pheochromocytoma patients and their relatives indicated that the large 
majority of mutations in SDH subunits or co-factors involve SDHD, followed by SDHB 
and SDHAF2 mutations, whereas SDHC mutations are extremely rare. The majority of 
SDH mutation carriers in the Netherlands harbour one specific mutation of SDHD, 
p.Asp92Tyr (chapter 2). This mutation alone accounts for 69% of all mutations in genes 
encoding subunits of the SDH complex. Several very large families residing in the western 
part of the Netherlands have been linked to this mutation and a strong founder effect has 
been demonstrated (1). Compared to the high prevalence of SDHD mutations in The 
Netherlands (87%), SDHB mutations are strikingly less common (6%). The majority of 
SDHB mutation carriers also have one of the two known Dutch founder mutations: 
c.423+1G>A or c.201-4429_287-933del (2;3). 
These results differ from international studies in other countries, which show either a two-
fold higher frequency of SDHB mutations carriers (4), a two-fold higher frequency of 
SDHD-related patients (5), or approximately equal numbers (6;7), but none showed the 14-
fold higher frequency found in The Netherlands. These differences in mutation prevalences 
can be explained by the unusual social and demographic history of our country, factors that 
might have contributed to the prevalence of a notable number of founder mutations in other 
genes (8). The Netherlands showed high levels of endogamy, marriage within groups, these 
groups defined by religious, geographic, or linguistic isolation, or a combination of these 
factors (9). The isolation of communities due to religious barriers to intermarriage was 
perhaps the most enduring factor, lasting well into the twentieth century, but occupational 
and geographic isolation were also important factors. These obstacles to intermarriage led 
to the creation of many genetically isolated populations. Such populations facilitate the 
proliferation of founder mutations and the well-known Dutch SDHD founder mutation, 
p.Asp92Tyr, shows a specific geographic focus even today (10). The region harboring the 
largest p.Asp92Tyr related pedigree also remained Catholic despite the overwhelming 
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dominance of the Protestant religion in surrounding areas. The prevalence of this specific 
SDHD mutation is therefore most likely attributable to endogamy, this effect perhaps 
amplified by limited migration, and rapid population growth in the 20
th
 century (11). The 
absence of a similar effectin the case of SDHB mutations is probably due to simple chance. 
Clinical implications: As mutations of SDHB, SDHC, SDHD and SDHAF2 each result in 
distinct hereditary paraganglioma syndromes, with differing modes of inheritance, 
penetrance, risk of pheochromocytoma, and risk of malignant paraganglioma, the 
identification of the affected gene is essential in providing effective genetic counselling to 
the individual paraganglioma patient. To date, several algorithms for prioritizing the order 
of gene-specific mutation testing in paraganglioma patients have been proposed, with the 
objectives of minimizing mutation screening and cost reduction (12;13). While these 
algorithms represent a very useful departure point for genetic analysis, it is doubtful 
whether the effectiveness and outcome of such algorithms is universally applicable, as the a 
priori chance of finding a mutation in a specific gene differs from country to country. 
Knowledge of these regional differences in the prevalence of mutations will facilitate the 
tailoring of genetic screening protocols to local circumstances. 
III. Biochemical screening of patients with head and neck paragangliomas 
Head and neck paragangliomas have the ability to produce and secrete catecholamines. 
Erickson et al. reported that a small proportion (4%) of benign HNPGLs were 
hyperfunctional (14). In 2005 van Houtum et al. documented that the prevalence of 
catecholamine excess in our SDHD-linked HNPGL patients was much higher than 
previously appreciated (15). At the time of that study, 15 of 40 consecutive patients 
(37.5%) had elevated levels of urinary catecholamine excretion. Pheochromocytomas or 
extra-adrenal paragangliomas were identified in 8 of these 15 patients (20%), indicating 
that HNPGL may be responsible for excess catecholamine secretion in about 17.5% of the 
cases included in their study. Importantly, they found no relationship between the levels of 
catecholamine excess and the complaints generally attributed to catecholamine excess. In 
chapter 3 we describe the results of biochemical screening in 136 patients with HNPGLs. 
Thirty-nine (29%) of the 136 included patients had excessive urinary excretion rates of 
catecholamines. The majority of the patients with a biochemical active tumor (31 of 136 
patients, 23%) had increased urinary excretion of 3-methoxytyramine (3MT), associated 
with increased dopamine excretion. Patients with 3MT excess had significantly more 
complaints of palpitations (p<0.01), diaphoresis (p=0.03), collapse (p<0.05) and a higher 
pulse rate (p<0.01). Increased excretion of 3MT was not associated with particular types of 
HNPGL or genotypes.  
It was unknown whether plasma catecholamine levels, including 3MT, were more sensitive 
parameters of biochemical activity of HNPGL than urinary excretion rates. For the 
diagnosis of pheochromocytoma, the measurement of plasma free metanephrine levels is 
the optimal biochemical test with the highest sensitivity and specificity (16). Therefore, in 
chapter 4 we studied whether plasma free metanephrines and 3MT levels are more 
sensitive tests to detect biochemical activity of HNPGL than urinary excretion rates of 
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catecholamines and 3MT. We screened 124 HNPGL patients for catecholamine excess by 
measurement of 24-hr urinary excretion rates of (nor)metanephrine, (nor)epinephrine, 
vanillylmandelic acid (VMA), dopamine and 3MT and plasma levels of (nor)metanephrine 
and 3MT. Plasma 3MT levels were increased in 35 of the 124 patients (28%), whereas 24-h 
urinary excretion rates of 3MT were increased in 30 patients (24%) (p=0.13). Plasma 
combined metanephrine levels (NMN, MN, 3MT) were increased in 41 patients (33%), 
whereas 24-h urinary excretion rates of combined metanephrines were increased in 33 
patients (27%, p<0.05). The combined assessment of plasma concentrations of free 
metanephrines and 3MT indicate a higher number of biochemically active HNPGL than the 
measurement of 24 h urinary excretion rates of combined metanephrines and 3MT. In 
addition, these data indicate that in HNPGL patients urinary excretion rates of deconjugated 
3MT and plasma free 3MT levels do not indentify significantly different numbers of 
subjects with biochemical active HNPGL.  
 
Clinical implications: Our results indicate that the number of patients with biochemical 
active HNPGLs is much higher than hitherto appreciated in studies that did not include the 
measurement of 3MT. We found that only part of the HNPGL patients with increased 
urinary excretion of 3MT also had increased urinary dopamine excretion. Therefore, 
urinary 3MT excretion is more sensitive in discovering dopamine-producing HNPGL than 
urinary dopamine excretion. We observed that the clinical manifestations in patients with 
increased 3MT excretion were different compared to those in patients with normal 
excretion of 3MT. Test sensitivity of plasma 3MT measurement equals the measurement of 
urinary deconjugated 3MT excretion. The combined assessment of plasma metanephrine 
levels (NMN, MN, 3MT) indicates a higher number of biochemical active tumors tumors 
than the measurement of 24 hour urinary excretion rates of combined metanephrines and 
catecholamines. 
IV. Chromogranin A as a tumor marker in patients with HNPGL 
Although HNPGL have the ability to produce and secrete catecholamines (17;18), we 
recently demonstrated that only 29% of patients with HNPGL have evidence of increased 
urinary excretion of catecholamines and/or their metabolites (19). Consequenly, the 
majority of these patients have biochemical silent tumors and the clinical characteristics of 
these HNPGL can be evaluated only by imaging techniques. Chromogranin A (CgA) is a 
secretory protein from neuroendocrine cells that mediates chromaffin granule biogenesis, 
necessary for catecholamine storage (20;21). CgA is secreted from neurosecretory vesicles, 
along with catecholamines (22). Plasma CgA is a useful tumor marker in patients with 
pheochromocytomas (23-29). Increased plasma levels of f chromogranin A  have been 
found in some patients with HNPGL, indicating the presence of secretory granules(30). In 
chapter 5 we present the results of the measurement of plasma chromogranin A (CgA) 
levels in patients with hereditary HNPGLs. Plasma CgA levels were increased in a minority 
of HNPGL patients, only 16% of all patients had increased plasma CgA levels. In the 
patients with biochemically inactive tumors, 15% had increased plasma CgA levels. 
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Therefore the practical implications of the measurement of CgA in HNPGL patients are 
limited. Interestingly, urinary excretion rates of noradrenaline and normetanephrine were 
positively related with plasma CgA levels. However, we found no relation between the 
urinary excretion rates of 3MT and dopamine and plasma CgA levels. This indicates that 
increased plasma CgA levels are associated with increased noradrenergic activity, but not 
with increased dopaminergic activity. This might indicate that the secretion of 
noradrenaline differs from the secretion of dopamine by HNPGL. However, at present the 
precise role of CgA in the monoamine sorting process in the chromaffin cells is still unclear 
and additional studies are required to elucidate the role of CgA in the sorting and transport 
of dopamine into granule vesicles.   
V. Pheochromocytomas detected by biochemical screening in predisposed subjects 
have a different clinical presentation compared to patients detected by signs and 
symptoms 
Pheochromocytomas are rare neuroendocrine tumors derived from chromaffin tissue within 
the adrenal medulla (31). Pheochromocytomas can be caused by germline mutations in the 
von Hippel-Lindau gene (VHL), the RET gene (leading to MEN2), the neurofibromatosis 
type I gene (NF1) or one of the SDH genes encoding for subunits B, D and C of 
mitochondrial succinate dehydrogenase (32-38). Because of this hereditary predisposition, 
patients with germline mutations in the VHL, RET, NF1 and SDHx genes are screened for 
the development of pheochromocytomas. In chapter 6 we compared the differences in 
presentation, treatment and longterm follow-up of patients with pheochromocytomas 
detected by biochemical screening in hereditary syndromes predisposing for 
pheochromocytomas and patients with sporadic pheochromocytomas. Patients with 
hereditary tumors presented in an earlier stage of tumor formation with smaller tumors. The 
levels of catecholamine secretion correlated with tumor diameters. Therefore, patients with 
hereditary tumors had lower urinary excretion rates of catecholamines which resulted in a 
lower prevalence of signs and symptoms compared to the patients with sporadic tumors. 
Despite these differences in biochemical activity and the sizes of the pheochromocytomas 
there were no differences between both groups in peri-operative complications. This was 
probably related to careful pre- and (peri-) operative care with careful titration of alpha- and 
beta blocking drugs. Long term follow up revealed additional manifestations of disease in 
both groups of patients. In the patients with a documented hereditary predisposition several 
patients developed an additional pheochromocytoma in the contralateral adrenal gland, 
especially in the case of MEN 2A syndrome (39). In the sporadic group there were several 
patients with malignant pheochromocytomas. Therefore, long term follow up seems to be 
warranted in all pheochromocytoma patients, irrespective of initial presentation.  
 
Clinical implications: Patients at risk for developing a pheochromocytoma should be 
regularly screened. The diagnostic test of choice is the measurement of fractionated plasma 
and/ or urinary metanephrines (40). Patients with a SDHx mutation, MEN2 disease or Von 
Hippel- Lindau disease are advised to be screened for pheochromocytoma every 1-2 years, 
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depending on the mutation. In case of increased plasma/ urinary catecholamines or their 
metabolites, additional radiological investigation should be performed to identify the culprit 
lesion (41-44). The prevalence of pheochromocytoma is quite low in patients with 
Neurofibromatosis and therefore screening is not recommended in all patients, but it may 
be justified in those patients with neurofibromatosis with hypertension, or in those patients 
who will undergo provocative interventions, such as surgery or pregnancy (45). The age of 
initial screening is determined by the specific gene mutation (46). 
VI. Carotid body paragangliomas and sleep related complaints  
Quality of life (QoL) studies performed in patients with head and neck paragangliomas 
reported that HNPGL patients frequently reported fatigue, reduced exercise tolerance and 
impaired sleep associated with the presence of carotid body glomus tumors (47). To 
elucidate the pathophysiology between sleep related complaints in patients with carotid 
body glomus tumors we studied 9 patients with bilateral carotid body tumors (bCBT) and 9 
patients with bilateral carotid body resection for sleep disordered breathing by 
polysomnography (chapter 7).There was a high prevalence of sleep disordered breathing in 
patients with bilateral carotid body paragangliomas, but not in patients with bilateral 
resection of carotid body paragangliomas. Moreover, bCBT patients reported an impaired 
quality of life and a reduced daytime activity level compared to healthy controls. Sleep 
disordered breathing was associated with increased carotid body output, evidenced by an 
increased pheripheral chemoresponsiveness. The question arises whether the increased 
chemoresponsiveness in the bCBT patients is associated with mutations in the succinate 
dehydrogenase gene (SDH). Piruat et al. have tested whether mice with a partial SDHD 
deficit have altered carotid body function. They found that the loss of an SDHD allele 
results in an abnormal enhancement of resting CB activity. This CB overactivity was linked 
to glomus cell hypertrophy and hyperplasia (48). Therefore, the increased peripheral 
chemoresponsiveness in the bCBT patients might be the result of hyperplasia of carotid 
body cells, indicating that tumor formation in the carotid bodies leads to gain of function 
rather than loss of function. Intermittent hypoxia can lead to the development of systemic 
hypertension, heart failure, myocardial infarction and stroke (49). Therefore, it is important 
to treat sleep disordered breathing. The optimal treatment strategy for bCBT patients with 
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VIII. Summary 
The findings of the present thesis can be summarized in the following conclusions: 
 
1. In the Netherlands, the majority of SDHx mutation carriers harbor a mutation in 
the SDHD gene, followed by SDHB and SDHAF2 gene mutations, whereas SDHC 
mutations are extremely rare. 
 
2. Almost 90% of all SDH-related paraganglioma and pheochromocytoma cases in 
the Netherlands can be attributed to only 6 founder mutations. 
 
3. Twenty- nine percent of patients with head and neck paragangliomas have 
evidence of a biochemical active tumor. The majority of patients with biochemical 
active head and neck paragangliomas have increased urinary excretion of 3-
methoxytyramine, a metabolite of dopamine. 
 
4. Test sensitivity of plasma 3MT measurement equals the measurement of urinary 
deconjugated 3MT excretion. The combined assessment of plasma metanephrine 
levels (NMN, MN, 3MT) indicates a higher number of biochemical active tumors 
tumors than the measurement of 24h urinary excretion rates of combined 
metanephrines and catecholamines.  
 
5. Only a minority of HNPGL patients have increased plasma chromogranin A 
levels. T-herefore, the practical implications of the measurement of plasma 
CgAlevels are limited in HNPGL patients. 
 
6. Increased plasma CgA levels are associated with increased noradrenergic activity, 
but not with increased dopaminergic activity. This might indicate that the secretion 
of noradrenaline differs from the secretion of dopamine in HNPGL. 
 
7. Patients screened for pheochromocytoma, because of a hereditary predisposition, 
present with less signs and symptoms, lower urinary excretion rates of 
catecholamines, and smaller tumors than patients presenting with symptomatic 
pheochromocytomas. Despite these differences in biochemical activity and the 
sizes of pheochromocytomas there is no difference between patients in peri-
operative complications. 
 
8. Patients with bilateral carotid body tumors are at risk for developing sleep 
disordered breathing. Sleep disordered breathing is associated with increased 
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Enkele jaren geleden is de multidisciplinaire aanpak van het Leids Universitair Medisch 
Centrum (LUMC) ten aanzien van patiënten met hoofd-hals paragangliomen (head and 
neck paragangliomas, HNPGL) uitgebreid. Er werd besloten alle HNPGL patiënten die de 
afdelingen KNO, endocrinologie en/ of klinische genetica consulteerden te screenen op 
overmatige catecholamine excretie volgens een gestructureerd protocol. Het doel van de 
inclusie van alle HNPGL patiënten was om de klinische en biochemische karakteristieken 
van deze patiënten verder te onderzoeken. De initiële screening bestaat uit het bepalen van 
de uitscheiding van catecholamines en de O-gemethyleerde metabolieten in 24-uurs urine in 
duplo. Deze screening wordt elke twee jaar uitgevoerd.. Patiënten met een verhoogde 
catecholamine excretie, ondergaan additioneel onderzoek in de vorm van 
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scintigrafie en MRI en/ of CT om additionele (extra-) adrenale paragangliomen uit te 
sluiten. 
 
In dit proefschrift beschrijven we de genetische, biochemische en klinische karakteristieken 
van patiënten met hoofd-hals paragangliomen. Als aanvulling op het meten van de 
catecholamine excretie in de urine, hebben we de plasma concentraties gemeten van de 
catecholamine metabolieten en vervolgens bepaald welke test de hoogste sensitiviteit 
behaalde. Verder hebben we de rol van het chromogranine A als tumor marker geëvalueerd 
in patiënten met HNPGL.  
In een eerdere studie, uitgevoerd door Bas Havekes et al. werd een verband gelegd tussen 
glomus caroticum tumoren en slaap gerelateerde klachten. Om deze slaap gerelateerde 
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klachten verder te specificeren hebben we patiënten met bilaterale glomus caroticum 
tumoren gescreend op slaapapneusyndroom. 
II. Prevalentie van mutaties van succinaat dehydrogenase in Nederland 
Hereditair paraganglioom syndroom wordt veroorzaakt door mutaties in het succinaat 
dehydrogenase (SDH) gen. De familie van SDH genen (SDHA, SDHB, SDHC en SDHD) 
coderen voor de vier subunits van complex II van de mitochondriële elektron transport 
keten. SDH is betrokken bij energie metabolisme als component van de citroenzuur cyclus. 
SDH zet succinaat om in fumaraat en dient als bron voor elektronen tijdens de 
mitochondriële respiratie, als complex II van de elektron transport keten. Omdat 30% van 
de patiënten met een veronderstelt sporadisch hoofd-hals paraganglioom een SDHx mutatie 
hebben, moeten alle patiënten met hoofd hals paragangliomen moleculair genetisch 
gescreend worden. Het LUMC is een toegewijd verwijs centrum voor patiënten met 
paragangliomen in Nederland. Omdat bijna alle DNA samples van Nederlandse 
paraganglioom patiënten in het LUMC geanalyseerd worden, zijn de uitkomsten van deze 
analyse representatief voor de SDHx mutatie frequentie prevalentie in Nederland. Analyse 
van 692 patiënten met paragangliomen en feochromocytomen en hun familieleden 
indiceren dat de meerderheid van de mutaties in SDH subunits of cofactoren gelegen zijn in 
het SDHD gen, gevolgd door het SDHB en het SDHAF2 gen mutaties, terwijl mutaties in 
het SDHC gen zeer zeldzaam zijn. De meerderheid van de SDH mutatie dragers in 
Nederland heeft één specifieke mutatie in het SDHD gen, de p.Asp92Tyr mutatie 
(hoofdstuk 2). Deze mutatie komt voor bij 69% van alle SDH mutatie dragers. 
Verscheidene grote families, woonachtig in het westen van Nederland zijn in verband 
gebracht met deze mutatie en een sterk ‘founder’ effect is aangetoond (1). Vergeleken met 
de hoge prevalentie van SDHD mutaties in Nederland (87%), komen SDHB mutaties veel 
minder vaak voor (6%). De meerderheid van de SDHB mutatie dragers heeft ook één van 
de twee bekende Nederlandse founder mutaties: c.423+1G>A of c.201-4429_287-933del 
(2;3). 
 
Deze resultaten verschillen van de uitkomsten van andere internationale studies. Deze laten 
of een tweevoudig hogere frequentie van SDHB mutatie dragers (4), of een tweevoud 
hogere frequentie van SDHD mutatie dragers (5), of ongeveer gelijke aantallen (6;7). 
Echter, geen van deze studies laat een 14-voudig verschil zien, zoals in Nederland. Dit 
verschil in mutatie prevalentie kan worden verklaard door de ongewone sociale en 
demografische geschiedenis van ons land, factoren die hebben bijgedragen aan de 
prevalentie van een opmerkelijk aantal founder mutaties in andere genen (8). In Nederland 
was er een aanzienlijke endogamie, huwelijk binnen groepen. Deze groepen werden 
gedefinieerd door religieuze, geografische of linguïstische isolatie of door een combinatie 
van deze factoren (9). De isolatie van gemeenschappen, vanwege religieuze barrières, was 
waarschijnlijk de meest langdurige factor, welke voortdurende tot in de twintigste eeuw, 
maar beroeps- of geografische isolatie waren ook belangrijke factoren. Dit obstakel tegen 
gemengde huwelijken leidde tot genetisch geïsoleerde populaties. Deze populaties 
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faciliteren de proliferatie van founder mutaties en de welbekende Nederlandse founder 
mutatie p.Asp92Tyr, laat ook tegenwoordig nog een specifieke geografische focus zien 
(10). Het gebied dat de grootste p.Asp92Tyr gerelateerde familie laat zien bleef ook 
katholiek, ondanks de aanzienlijke dominantie van het protestantisme in de omliggende 
gebieden. De prevalentie van deze specifieke SDHD mutatie is daarom waarschijnlijk het 
gevolg van endogamie en dit effect is waarschijnlijk vergroot door de gelimiteerde migratie 
en snelle groei van de populatie in de 20
e
 eeuw (11). De afwezigheid van dit effect bij 
SDHB dragers is waarschijnlijk het effect van kans. 
 
Klinische implicaties: Omdat SDHB, SDHC, SDHD en SDHAF2 mutaties elk resulteren in 
een verschillend fenotype, met verschillende wijzen van overerving, penetrantie, 
verschillende risico’s op feochromocytomen, en op maligne paragangliomen, is de 
identificatie van het aangedane gen essentieel in het bieden van adequate genetische 
counseling aan de individuele patiënt met paragangliomen. Er bestaan verschillende 
algoritmes om de juiste volgorde van testen van gen mutaties te bepalen, met het doel het 
testen van mutaties zo effectief en kosten besparend te verrichten (12;13). Deze algoritmes 
zijn zeer nuttig bij het bepalen van het traject van mutatie testen, maar deze algoritmes zijn 
niet zonder meer universeel toepasbaar, omdat de a priori kans op het vinden van een 
mutatie in een specifiek gen verschilt van land tot land. Kennis van regionale verschillen in 
de prevalentie van deze mutaties zal het opstellen van screenings protocollen toegepast op 
een specifieke regio faciliteren. 
III. Biochemische screening van patiënten met hoofd-hals paragangliomen 
Hoofd-hals paragangliomen (HNPGL) produceren catecholamines. Erickson et al. 
rapporteerden dat 4% van de benigne HNPGL hyperfunctioneel waren. In 2005 
concludeerden  van Houtum et al. dat de prevalentie van catecholamine producerende 
paragangliomen  in onze SDHD-gerelateerde HNPGL patiënten veel hoger was dan eerder 
werd verondersteld (15). In zijn studie werd gerapporteerd dat 15 van de 40 patiënten 
(37.5%) een verhoogde uitscheiding van catecholamines in de urine had. Een 
feochromocytoom of (extra-) adrenaal paraganglioom werd aangetoond in 8 van deze 15 
patiënten (20%). Dit indiceerde dat HNPGL verantwoordelijk zouden zijn voor een 
verhoogde urinaire catecholamine excretie in ongeveer 17.5% van de geïncludeerde 
casussen. Het is belangrijk te vermelden is dat er geen associatie was tussen de mate van 
catecholamine excretie en klachten die veroorzaakt zouden kunnen worden door 
catecholamine exces.  
In hoofdstuk 3 beschrijven we de resultaten van de biochemische screening in een veel 
grotere serie van patiënten: 136 patiënten met HNPGL. Negenendertig (29%) van de 136 
geïncludeerde patiënten had een verhoogde catecholamine excretie in de urine. De 
meerderheid van de patiënten met een biochemisch actieve tumor (31 van de 136 patiënten, 
23%) had een verhoogde excretie van 3-methoxytyramine (3MT) in de urine, geassocieerd 
met een verhoogde dopamine excretie. Patiënten met een verhoogde 3MT excretie hadden 
significant meer klachten van palpitaties, zweten, collaps en een hogere polsfrequentie. Een 
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verhoogde 3MT excretie was niet geassocieerd met een specifiek type HNPGL of een 
specifiek genotype.  
 
Het meten van plasma metanefrine concentraties is de optimale biochemische test met de 
hoogste sensitiviteit en specificiteit voor het aantonen van een feochromocytoom (16). In 
hoofdstuk 4 bespreken we de testgevoeligheid van plasma vrije metanefrines, inclusief 
3MT, versus de excretie van catecholamines en metanefrines in de urine om een 
biochemisch actieve HNPGL aan te tonen. We screenden 124 HNPGL patiënten op een 
verhoogde catecholamine secretie door het meten van (nor)metanefrine, (nor)adrenaline, 
vanillylmandelic acid (VMA), dopamine en 3MT in 24-uurs urine en (nor)metanefrine en 
3MT in plasma. Plasma 3MT concentraties waren verhoogd in 35 van de 124 patiënten 
(28%) en de excretie van 3MT in 24-uurs urine was verhoogd in 30 patiënten (24%) 
(p=0.13). Gecombineerde plasma metanefrine concentraties (NMN, MN, 3MT) waren 
verhoogd in 41 patiënten (33%), terwijl deze parameters bij 33 patiënten in de 24-uurs urine 
verhoogd waren (27%, p<0.05). De beoordeling van plasma concentraties van de vrije 
metanefrines en 3MT indiceren een hoger aantal biochemisch actieve HNPGL dan het 
meten van de gedeconjugeerde metabolieten in 24-uurs urine. Onze data tonen aan dat het 
meten van gedeconjugeerd 3MT in de 24 uurs urine en het vrije 3MT in plasma geen 
significant verschil in aantal biochemische actieve HNPGL aantonen.  
 
Klinische implicaties: onze resultaten indiceren dat het percentage HNPGL patiënten met 
een biochemisch actieve tumor aanzienlijk hoger is dan werd vermeld in eerdere studies, 
die het 3MT niet beoordeelden. Wij toonden aan dat slechts een klein deel van de patiënten 
met een verhoogde 3MT excretie in de urine ook een verhoogde dopamine excretie in de 
urine hadden. Daarom is de meting van 3MT in de urine een sensitievere marker voor het 
aantonen van een dopamine  producerend paraganglioom dan de meting van dopamine 
excretie in de urine. We zagen een verschil in klinische manifestaties tussen patiënten met 
een verhoogd 3MT en een normaal 3MT. De test sensitiviteit van plasma vrij 3MT is gelijk 
aan de sensitiviteit van het meten van gedeconjugeerd 3MT in de urine. Het meten van de 
plasma vrije metanefrines (NMN, MN, 3MT) indiceert een hoger aantal biochemisch 
actieve HNPGL vergeleken met het meten van deze metabolieten in gedeconjugeerde vorm 
en catecholamines in 24-uurs urine.  
IV. Chromogranine A als tumor marker voor patiënten met hoofd-hals 
paragangliomen 
Hoewel HNPGL catecholamines kunnen produceren en uitscheiden (17;18), toonden we 
recent aan dat slechts 29% van deze patiënten een verhoogde catecholamine excretie 
hadden in 24-uurs urine (19). De meerderheid van deze patiënten heeft dus een 
biochemisch inactieve tumor en de klinische karakteristieken van deze HNPGL patiënten 
kan alleen met behulp van beeldvormend onderzoek aangetoond worden. Chromogranine A 
is een secretoir proteïne afkomstig uit neuro-endocriene cellen dat de chromaffiene granuul 
biogenese faciliteert, belangrijk voor de opslag van catecholamines. CgA wordt samen met 
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de catecholamines uit neurosecretoire blaasjes gesecerneerd (22). Plasma CgA is een 
bruikbare tumor marker voor patiënten met feochromocytomen (23-29). Verhoogde plasma 
levels van chromogranine A zijn aangetoond bij enkele patiënten met HNPGL, hetgeen past 
bij de aanwezigheid van secretoire granules in HNPGL (30). In hoofdstuk 5 presenteren 
we de resultaten van de metingen van plasma CgA in patiënten met erfelijke HNPGL. 
Plasma CgA concentraties waren verhoogd in slechts een klein deel van de patiënten met 
HNPGL: slechts 16% van alle patiënten had een verhoogd plasma CgA. Van de patiënten 
met een biochemisch inactieve tumor had slechts 15% een verhoogd plasma CgA 
concentratie. Daarom zijn de praktische implicaties van de bepaling van plasma CgA 
spiegels bij patiënten met HNPGL beperkt. Er was een positieve correlatie tussen de urine 
excretie ratio’s van noradrenaline en normetanefrine en plasma CgA concentraties. We 
vonden echter geen associatie tussen urine excretie van 3MT en dopamine enerzijds en 
plasma CgA concentraties anderzijds. Dit betekent dat verhoogde plasma CgA 
concentraties geassocieerd zijn met een verhoogde noradrenerge activiteit, maar niet met 
een verhoogde dopaminerge activiteit. Dit zou betekenen dat de secretie van noradrenaline 
verschilt van de secretie van dopamine uit HNPGL. Echter, de precieze rol van 
chromogranine A in het monoaminen sorterings proces in de chromaffiene cellen blijft nog 
steeds onduidelijk en verder onderzoek is nodig om de rol van CgA in het sorteren en 
transporteren van dopamine in de secretoire granules uit te zoeken.  
V. Feochromocytomen opgespoord met biochemische screening van patiënten met 
een genetische predispositie presenteren zich anders dan sporadische 
feocromocytomen die ontdekt worden bij patiënten met symptomen 
Feochromocytomen zijn zeldzame neuro-endocriene tumoren afkomstig van chromaffien 
weefsel uit de adrenale medulla (31). Een feochromocytoom kan veroorzaakt worden door 
kiemcel mutaties in het Von-Hippel Lindau gen (VHL), het RET gen (MEN2), het 
neurofibromatose type I gen (NF1), of één van de SDH genen die coderen voor subunits B, 
D en C van het mitochondriale succinaat dehydrogenase (32-38). Vanwege deze erfelijke 
predispositie, worden patiënten met kiemcel mutaties in de VHL, RET, NF1 en SDHx 
genen gescreend op de ontwikkeling van een feochromocytoom. In hoofdstuk 6 
vergelijken we de verschillen in presentatie, behandeling, en langdurige follow-up van 
patiënten met feochromocytomen als gevolg van een erfelijk syndroom opgespoord met 
biochemische screening vergeleken met patiënten met sporadische feochromocytomen. 
Patiënten met erfelijke tumoren presenteerden zich in een eerder stadium van tumor 
vorming met kleinere tumoren. De mate van catecholamine excretie is gecorreleerd aan 
tumor diameter. Daarom hadden de patiënten met erfelijke tumoren een lagere 
catecholamine excretie in de urine en presenteerden zij zich met minder symptomen dan de 
patiënten met sporadische tumoren. Ondanks deze verschillen in biochemische activiteit en 
de grootte van de tumoren was er geen verschil tussen beide groepen ten aanzien van 
perioperatieve complicaties. Waarschijnlijk was dit het gevolg van nauwkeurige pre- en 
(peri-)operatieve zorg met nauwkeurige titratie van alfa- en beta-receptor blokerende 
medicatie. Langdurige follow-up toonde additionele manifestaties van de ziekte aan in 
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beide groepen patiënten. In de patiëntengroep met een aangetoonde erfelijke predispositie 
ontwikkelden verscheidene patiënten een feochromocytoom in de contralaterale bijnier, 
voornamelijk bij de patiënten met MEN 2A syndroom (39). In de sporadische groep waren 
er verscheidene patiënten met een maligne feochromocytoom. Langdurige follow-up is 
geïndiceerd van alle patiënten met feochromocytomen, ongeacht de initiële presentatie.  
 
Klinische implicaties: patiënten met een verhoogd risico op het ontwikkelen van een 
feochromocytoom moeten regelmatig gescreend worden. De diagnostische test van keuze is 
het meten van de gefractioneerde metanefrines in plasma en/ of urine (40). Patiënten met 
een SDHx mutatie, MEN 2A of Von-Hippel Lindau worden geadviseerd zich om de één of 
twee jaar te laten screenen (termijn is afhankelijk van het type mutatie) op de ontwikkeling 
van een feochromocytoom. In het geval van een verhoogde catecholamine excretie in 
plasma of urine, moet er aanvullend beeldvormend onderzoek verricht worden om de laesie 
op te sporen (41-44). De prevalentie van feochromocytomen is laag bij patiënten met 
neurofibromatose en daarom wordt screening niet geadviseerd aan alle patiënten, maar is 
screening wel gerechtvaardigd in die patiënten met hypertensie of degenen die provocatieve 
interventies ondergaan, zoals chirurgie of zwangerschap (45). De leeftijd waarop screening 
gestart moet worden wordt bepaald door de specifieke gen mutatie (46).  
VI. Glomus caroticum tumoren en slaap gerelateerde klachten 
Kwaliteit van leven studies uitgevoerd onder patiënten met hoofd-hals paragangliomen 
rapporteerden dat HNPGL patiënten frequent klachten hebben van vermoeidheid, 
gereduceerde inspanningstolerantie en een verstoorde slaap welke gerelateerd zijn aan de 
aanwezigheid van glomus caroticum tumoren (47). Om de relatie tussen slaap gerelateerde 
klachten bij patiënten met glomus caroticum tumoren nader te analyseren, onderzochten we 
9 patiënten met bilaterale glomus caroticum tumoren (bCBT) en 9 patiënten met een 
bilaterale resectie van het glomus caroticum (bCBR) op slaap apneu syndroom met behulp 
van polysomnografie (hoofdstuk 7). De prevalentie van het slaap-apneu syndroom was 
hoog onder de patiënten met bilaterale glomus caroticum tumoren, maar niet onder de 
patiënten met een bilaterale glomus caroticum resectie. Verder rapporteerden de bCBT 
patiënten een verminderde kwaliteit van leven en een gereduceerd activiteitsniveau 
gedurende de dag vergeleken met gezonde controles. De aanwezigheid van het slaap apneu 
syndroom bleek geassocieerd te zijn met een verhoogde output van het glomus caroticum, 
wat tot uiting kwam in een toegenomen chemosensitiviteit. De vraag doemt op of een 
toegenomen chemosensitiviteit in de bCBT patiënten het gevolg is van een mutatie in het 
succinaat dehydrogenase gen (SDH). Piruat et al. onderzochten of muizen met een partieel 
SDH defect een verandering in glomus caroticum activiteit hadden. Zij toonden aan dat het 
verlies van een SDHD allel resulteerde in een abnormale toename van de activiteit van het 
glomus caroticum in rust. Deze glomus caroticum hyperactiviteit werd geassocieerd met 
glomus cel hypertrofie en hyperplasie (48). De toegenomen perifere chemosensitiviteit in 
de bCBT patiënten zou het resultaat kunnen zijn van hyperplasie van de cellen van het 
glomus caroticum, wat indiceert dat tumor formatie in de glomus carotica leidt tot een 
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toename van de CB activiteit in plaats van een afgenomen activiteit. Intermitterende 
hypoxie kan leiden tot de ontwikkeling van systemische hypertensie, hartfalen, myocard 
infarct en beroertes (49). Daarom is het belangrijk om slaap apneu syndroom te behandelen. 
De optimale behandelings methode van slaap apneus bij bCBT patiënten moet nog 
onderzocht worden. 
VII. samenvatting 
Mijn proefschrift heeft de volgende conclusies opgeleverd: 
 
I. In Nederland heeft de meerderheid van de SDHx mutatie dragers een mutatie in 
het SDHD gen, gevolgd door SDHB en SDHAF2 gen mutaties. SDHC mutaties 
zijn zeer zeldzaam. 
 
II. Bijna 90% van alle SDH-gerelateerde paragangliomen en feochromocytomen 
casussen in Nederland worden veroorzaakt door slechts 6 founder mutaties. 
 
III. Negentwintig procent van de patiënten met hoofd-hals paragangliomen hebben 
aanwijzingen voor een biochemisch actieve tumor. De meerderheid van de 
patiënten met een biochemisch actieve tumor hebben een verhoogde excretie van 
3-methoxytyramine, een metaboliet van dopamine, in de urine.  
 
IV. De test sensitiviteit van plasma vrij 3MT  is gelijk aan de test sensitiviteit van 
gedeconjugeerd 3MT in 24-uurs urine. De meting van de gecombineerde plasma 
vrije metanefrines (NMN, MN, 3MT) toont een hoger aantal biochemisch actieve 
tumoren aan dan het meten van de gecombineerde gedeconjugeerde metanefrines 
en catecholamines in 24-uurs urine. 
 
V. Slechts een klein deel van de patiënten met hoofd-hals paragangliomen heeft een 
verhoogde plasma chromogranine A spiegel. Daarom zijn de praktische 
implicaties van de meting van plasma chromogranine A concentraties in patiënten 
met HNPGL beperkt.  
 
VI. Een verhoogde plasma chromogranine A concentratie is geassocieerd met een 
toegenomen nor-adrenerge activiteit, maar niet met een toegenomen dopaminerge 
activiteit. Dit indiceert dat de secretie van noradrenaline verschilt van de secretie 
van dopamine door HNPGL. 
 
VII. Patiënten met een erfelijke predispositie die gescreend worden op een 
feochromocytoom, presenteren zich met minder symptomen, lagere catecholamine 
excretie in de urine en kleinere tumoren vergeleken met patiënten die zich 
presenteren met symptomatische feochromocytomen. Ondanks de verschillen in 
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biochemische activiteit en de grootte van de feochromocytomen is er geen verschil 
tussen de patiënten in perioperatieve complicaties. 
 
VIII. Patiënten met bilaterale glomus caroticum tumoren hebben een verhoogd risico op 
slaap apneu syndroom. Bij deze patiënten is dit slaap apneu syndroom 
geassocieerd met een toegenomen activiteit van het glomus caroticum, wat tot 
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